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The aim of this thesis on primary hyperparathyroidism (PHPT) was to improve 
preoperative imaging, to evaluate the effect of parathyroidectomy on health-related 
quality of life, and to investigate parathyroid carcinoma and its incidence in Finland. 
 
PHPT is due to a parathyroid adenoma (in 80%), hyperplasia in two or more 
glands (15–20%) or, rarely, to parathyroid carcinoma. The only definitive treatment 
is an operation, which is indicated if surgical criteria are met. Preoperative imaging 
localizing the pathological gland(s) in the neck allows 70% of parathyroidectomies 
to be targeted. Otherwise, all four glands are explored. In our retrospective study of 
269 PHPT patients who have undergone primary operation, the planar 
123iodine/99mTechnetium(Tc)-sestamibi scintigraphy and 99mTc-sestamibi 
scintigraphies were accurate in 61% and 34% of patients, respectively. The cure rate 
was 93%, but 61% in those with multigland disease (16% of the cohort). The gland 
size, serum calcium and PTH concentrations correlated to the proportion of 
scintigraphy findings. 
 
In the reoperative setting, preoperative imaging has a crucial role, as the risk of 
surgery complications is higher. In our prospective study of 21 PHPT patients 
planned for reoperation, the imaging results were accurate in 59% of 123iodine/99mTc-
sestamibi scintigraphies, in 19% of 99mTc-sestamibi-SPECT/CT, in 65% of 11C-
methionine-PET/CT, and in 40% of selective venous sampling studies (SVS). False 
positives were present in nearly half (9 out of 20) of SVSs but only in one PET/CT 
study.  
 
In our prospective study of 124 PHPT patients, the preoperative health-related 
quality of life (HRQoL) studied with the 15D- instrument was lower than in a 
comparable sample of the general Finnish population (n=4295). It increased after 
surgery and was sustained in a one-year follow-up. The change in HRQoL was 
clinically significant in 77.4% of patients. Serum calcium and parathormone 
concentrations did not correlate with the preoperative level or the postoperative 
change of HRQoL. 
 
Parathyroid carcinoma (PC) often presents with more severe PHPT than in the 
benign disease. We noticed that the incidence of PC has markedly increased in 
recent decades, with one case in 1 000 000 persons per year between 2010 and 2013. 
With our national research group, we collected and analyzed all the 32 PC cases and 
their tissue specimen diagnosed in Finland between 2000 and 2011. We compared 
these to 28 atypical adenoma and 72 age- and gender-adjusted parathyroid adenoma 
cases. Tissue Micro Array (TMA) analysis was performed on all tissue samples. 
Mutation analysis of the CDC73 gene related to PC was performed on 56% and 57% 
PC and atypical adenomas respectively, and was positive in 6% in both groups. PC 
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patients had higher serum calcium and PTH concentrations, and more often both 
bone and kidney manifestations.  
 
The diagnosis of PC is based on metastasis or capsular, vascular or neural 
invasion, which can be challenging to diagnose. An atypical adenoma lacks the signs 
of invasion but has other features concordant with PC. In our study, the presence of 
lymph node metastasis at diagnosis, negative parafibromin staining, and a 
proliferation index of over 5% seemed to be related to a more aggressive disease. All 
recurrent tumors had a vascular invasion. PC has been reported to recur in 40–60% 
of patients. Therefore, it is recommended that the primary operation is more radical 
than a routine parathyroidectomy. At the seven-year follow-up, 21% had a 
recurrence of PC, and half of the patients were operated on at least twice. The 
mortality of the PC group did not differ from other subgroups, although in the PC 
group four died of the disease. One of the atypical adenoma patients had a 
recurrence. 
 
In conclusion, the use of a thyroid-specific tracer like 123Iodine improves the 
accuracy of planar 99mTc-MIBI scintigraphy. In multigland disease, representing 
16% of the cases, the accuracy of 123Iodine/99mTc-sestamibi scintigraphy is markedly 
lower compared to single gland disease. Before reoperation, if ultrasound and 
scintigraphy findings are discordant or negative, 11C-methionine-PET/CT is 
recommended. The HRQoL in PHPT patients is reduced compared to healthy 
controls, but it improves significantly after operation. The incidence of parathyroid 
carcinoma is increased and it should be suspected if serum ionized calcium exceeds 
1.70 mmol/l. PC patients often need reoperations, but the recurrence rate is lower 


















Väitöskirjatyöni tavoitteena oli kehittää primaarin hyperparatyreoosin (PHPT) 
preoperatiivisia paikantamismenetelmiä, arvioida lisäkilpirauhasleikkauksen 
vaikutusta terveyteen liittyvään elämänlaatuun sekä lisäkilpirauhassyövän yleisyyttä 
ja taudinkulkua Suomessa. Tutkimukset tehtiin vuosina 2009-2016. 
 
PHPT:ssa hyperkalsemian syynä on lisääntynyt lisäkilpirauhashormonin (PTH) 
eritys, jonka taustalla on 80-85%:ssa lisäkilpirauhasadenooma, 15-20%:ssa 
useamman rauhasen hyperplasia ja 1–3%:lla lisäkilpirauhassyöpä. Taudin ainoa 
parantava hoito on leikkaus, joka on tarpeen jos leikkausaiheet täyttyvät. Ennen 
leikkausta isotooppi- ja ultraäänitutkimuksilla selvitetään, mikä/mitkä kilpirauhasen 
takapinnalla sijaitsevista 4-5 lisäkilpirauhasesta on poikkeava. Noin 70% 
leikkauksista voidaan tehdä kohdennetusti, muutoin etsitään kaikki lisäkilpirauhaset. 
Vertasimme 269 PHPT:n vuoksi ensi kertaa leikatun joukossa parantaako 123jodi-
kuvauksen lisääminen kaksivaiheisen 99mTeknetium(Tc)-sestamibi-
isotooppikuvauksen tuloksia. Koko aineistossa 61%:ssa 123jodi/99mTc-MIBI-kuvista 
ja 34%:ssa 99mTc-MIBI-kuvista oli yhden poikkeavan rauhasen löydös, joka vastasi 
leikkauslöydöstä, eikä muita sairaita rauhasia todettu. Koko aineistossa leikkaus 
onnistui 93%:lla, mutta useamman rauhasen taudissa (16%:lla) vain 61%:lla leikkaus 
onnistui. Mitä suurempi lisäkilpirauhaskasvain oli ja mitä korkeammat olivat veren 
kalsium- ja PTH-tasot, sitä todennäköisemmin kasvain löytyi isotooppikuvauksessa.  
 
Osalla potilaista tauti jatkuu ensileikkauksen jälkeen. Ennen uusintaleikkausta 
paikantamistutkimukset ovat erityisen tärkeitä suurentuneen komplikaatioriskin 
vuoksi. Vertasimme 21 PHPT:n vuoksi uusintaleikattavan henkilön aineistossa eri 
paikantamismenetelmiä. Leikkaus- ja kuvantamislöydökset olivat yhdenmukaiset 
59%:lla 123jodi/99mTc-sestamibi-isotooppikuvauksessa, 19%:lla 99mTc-sestamibi-
SPECT/CT:ssa, 65%:lla 11C-metioniini-PET/CT ja 40%:lla kaulalaskimoiden 
katetrisaatiotutkimuksessa. Kaulalaskimoiden katetrisaatiossa lähes puolella oli 
vääriä positiivisia löydöksiä, PET/CT-kuvauksessa niitä oli vain yhdellä.  
 
Seerumin kalsiumin määrityksen yleistyttyä PHPT 
diagnosoidaan n. 80%:ssa tapauksista vähäoireisena. Lievään tautiin voi liittyä 
väsymystä, kipuja ja neurokognitiivisia oireita, mutta ei ole selvää korjaantuvatko 
oireet leikkauksen jälkeen. Seurasimme 124 PHPT:a sairastavan henkilön terveyteen 
liittyvää elämänlaatua 15D-elämänlaatumittarin avulla ennen 
lisäkilpirauhasleikkausta ja vuoden ajan sen jälkeen. Vertasimme tuloksia ikä- ja 
sukupuolivakioituun suomalaiseen verrokkiväestöön (n=4295). PHPT-potilaiden 
preoperatiivinen elämänlaatu oli verrokkeja merkitsevästi alempi, mutta se parani 
leikkauksen jälkeen. Muutos oli kliinisesti merkittävä 77.4%:lla potilaista. Seerumin 
kalsium- tai parathormonipitoisuuksilla ei ollut yhteyttä preoperatiiviseen 




Lisäkilpirauhassyöpä (PC) aiheuttaa samanlaisen, mutta vaikeamman 
taudinkuvan kuin hyvänlaatuinen PHPT. Selvityksemme mukaan PC on yleistynyt 
viime vuosikymmeninä. Vuosina 2010-2013 ilmeni 1 tapaus vuodessa 1 000 000 
henkilöä kohti. Keräsimme ja analysoimme yhdessä kansallisen tutkijaryhmämme 
kanssa kaikki 32 Suomessa vuosina 2000-2011 todettua lisäkilpirauhassyöpätapausta 
sekä näiden kudosnäytteet. Vertasimme löydöksiä 28 atyyppiseen adenoomaan sekä 
72 adenoomaan. Teimme immunohistokemiallisia värjäyksiä Tissue Micro Array - 
menetelmällä. PC-potilailla oli diagnoosivaiheessa muita korkeammat seerumin 
ionisoitu kalsium- ja PTH-tasot, tautiin liittyvät luusto- ja munuaismuutokset, sekä 
sairaalahoitoon johtanut hyperkalsemia. Lisäkilpirauhassyöpään liittyvä CDC73- 
geenimutaatio tutkittiin 56% ja 57% PC ja atyyppisten adenoomien ryhmissä, 
molemmissa 6%:lla todettiin mutaatio. 
 
Lisäkilpirauhassyövän diagnoosi perustuu joko todettuihin etäpesäkkeihiin tai 
histologiseen invaasion osoittamiseen, mikä on vaativaa. Atyyppisessä adenoomassa 
invaasion merkit puuttuvat, mutta todetaan monia lisäkilpirauhassyövälle tyypillisiä 
histologisia piirteitä. Diagnoosivaiheen imusolmukemetastaasit, negatiivinen 
parafibromiinivärjäys ja proliferaatioindeksi (Ki-67) yli 5% näyttävät viittaavan 
aggressiivisempaan tautiin. Kaikissa uusiutuneissa kasvaimissa oli myös verisuoni-
invaasio. Lisäkilpirauhasyövän on aiemmin raportoitu uusiutuvan 40-60%:lla ja 
useimmin paikallisesti, siksi tavanomaista laajempi ensileikkaus on eduksi. 
Seitsemän vuoden seurannassa tauti uusiutui 21%:lle, puolet leikattin vähintään 
kahdesti. PC-ryhmän kuolleisuus ei eronnut muista. Yhdellä leikkauksessa 
parantuneista atyyppistä adenoomaa sairastaneista tauti uusiutui. 
 
Johtopäätöksinä todetaan, että lisäkilpirauhasten 99mTc-sestamibi-tasokuvauksen 
tarkkuus paranee käytettäessä kaksoisisotooppikuvausta yhden isotoopin 
menetelmään verrattuna. Useamman rauhasen taudissa poikkeavat rauhaset 
paikantuvat huonommin yhden rauhasen tautiin verrattuna, jolloin leikkaus voi jäädä 
epätäydelliseksi. Ennen uusintaleikkausta ultraääni- ja isotooppikuvausten jäädessä 
negatiivisiksi tai epäyhteneviksi suositellaan 11C-metioniini-PET/CT-kuvausta. 
PHPT-potilailla terveyteen liittyvä elämänlaatu on terveisiin verrokeihin nähden 
selvästi alentunut, mutta se paranee merkittävästi lisäkilpirauhasleikkauksen jälkeen. 
Lisäkilpirauhassyövän insidenssi Suomessa 2000-luvulla on noussut. Tautia tulisi 
epäillä PHPT-potilaalla, jos seerumin ionisoitu kalsium on yli 1.70 mmol/l. PC-
potilaat joutuvat edelleen usein uusintaleikkauksiin, mutta aiempiin raportteihin 
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Primary hyperparathyroidism (PHPT) is the most common cause for hypercalcemia 
(Marcocci, Cetani 2011) in which parathormone (PTH) is produced excessively from 
one or more of the four parathyroid glands (Bilezikian et al. 2016). The prevalence is 
1–4 per 1000 and is highest among elderly women. PHPT is due to a parathyroid 
adenoma (80%), two or more hyperplastic parathyroid glands (15–20%) or, rarely, 
parathyroid carcinoma. In 5–10% of cases, PHPT is part of a genetic syndrome such 
as multiple endocrine neoplasia (MEN) syndrome, hyperparathyroidism-jaw tumor 
(HPT-JT) syndrome, or familial hypocalciuric hypocalcemia (FHH) (Thakker 2016).  
Surgery is the only possible definitive treatment for PHPT. At diagnosis, patients 
are guided either to surgery or lifelong annual surveillance. The operation, bilateral 
exploration, includes the visualization of all four parathyroids and the removal of the 
enlarged one. However, multiglandular disease, present in 15–20% of patients, is 
more difficult to locate and complicates the choice of operation technique (Norman, 
Lopez & Politz 2012). Surgical techniques and especially the use of imaging to 
preoperatively locate the pathological gland have evolved (Bergenfelz et al. 2009). 
This enables focused parathyroidectomies with lower complication risks and shorter 
hospital stays. Patients with persistent or recurrent disease sometimes need 
reoperation, which is related to higher complication rates and require two concordant 
results in preoperative imaging studies (Hindie et al. 2009, Hindie et al. 2015). While 
the most commonly used methods, ultrasound and scintigraphy, remain discordant or 
negative, selective venous sampling (SVS) has long been the gold standard in the 
localization of an over-functioning parathyroid gland (Udelsman et al. 2009a).  
PHPT has been known as a disease which presents severe bone and renal changes 
as well as abdominal and psychiatric symptoms. In recent decades, the better 
availability of serum calcium measurement has led to earlier diagnosis of PHPT. 
Consequently, the clinical profile has shifted from an advanced to a mild disease. To 
date, up to 80% of patients have none or only subtle symptoms of PHPT at diagnosis 
(Marcocci, Cetani 2011). However, the most recent studies show that these 
asymptomatic patients still suffer from neuropsychological and cognitive symptoms 
as well as other non-specific symptoms. PHPT is associated with impaired health-
related quality of life, but it is still unclear as to whether the symptoms ameliorate 
and HRQoL improves after surgery, and if and when these symptoms justify surgery 
(Grant, Velusamy 2014).  
Parathyroid carcinoma (PC) is a rare endocrine cancer, causing 1–3% of PHPT 
cases (Cetani, Pardi & Marcocci 2016). In Finland, the proportion of diagnosed PC 
among parathyroid tumors seems to have increased during the last two decades. PC 
has a more severe clinical presentation than benign parathyroid tumors with 
symptoms due to hypercalcemia, not to tumor mass itself. PC patients suffer from 
successive recurrences (in 40–60% of cases), multiple reoperations and surgery 
complications (Harari et al. 2011). A third of patients die of the disease during six-
year follow-up periods (Talat, Schulte 2010). Distinguishing PC from benign or 
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atypical adenomas (APA) is often challenging. APAs are borderline tumors with 
features of PC but without invasion. PC patients need en bloc resection to provide 
the most effective chance of cure, and a closer post-operational follow-up (Schulte et 
al. 2012).  
The aim of this study was to investigate these current topics in the management 
of PHPT. We compared preoperative imaging methods and analyzed the effect of 
preoperative localization on surgical techniques and results of 269 patients who had 
undergone primary operation and reoperation, respectively, at Helsinki University 
Hospital. We followed the health-related quality of life (HRQoL) in 125 PHPT 
patients referred to surgery for one year postoperatively. We collected all 32 
parathyroid carcinomas diagnosed in Finland between 2000 and 2011 to assess the 
incidence, clinical and histological features of PC, and compared these to 28 atypical 
and 72 benign parathyroid adenomas. 
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2 REVIEW OF THE LITERATURE 
2.1 CALCIUM METABOLISM  
2.1.1 ROLE AND DISTRIBUTION OF CALCIUM  
 
Calcium is indispensable for life. Calcium and phosphorus are the main elements of 
the bone, constituting two-thirds of the weight of bone. Nearly all, 99%, of total 
body calcium is in bone, and 99% of that is within the crystal structure of the mineral 
phase. In bone, the concentrations of the remaining 1% of calcium are equal in the 
extra- and intracellular fluids. This soluble portion of calcium is important for bone 
and cartilage mineralization and a cofactor for many enzymes, for instance in the 
coagulation cascade.  
In blood, 50% of the calcium is bound to proteins, such as albumin and globulins. 
The ionized calcium concentration is 1.2 mmol/liter (5 mg/dl) on average. This 
biologically active form is tightly controlled. However, the intracellular calcium 
concentration is only 100 nmol/l, and there is a large chemical gradient (10000:1) 
with the extracellular fluid. This gradient provides rapid transition of calcium 
through calcium channels. Most of the intracellular calcium is bound to intracellular 
membranes and its release is tightly regulated.  
Calcium homeostasis is essential because of the key role of calcium in extra- and 
intracellular compartments. In extracellular fluid (ECF) (Figure 1), calcium functions 
in membrane excitability, in bone mineralization, and as an important cofactor in 
proteins (adhesion molecules, clotting factors, enzymes). The intracellular functions 
of calcium include muscle contraction, activating endocytosis, hormone secretion 




Figure 1. Distribution of different forms of calcium in blood plasma (adapted from 
Guyton and Hall, Textbook of Physiology 13th Edition) 
 
 
Ionized calcium (50%, 1.2 
mmol/l)
Calcium complexed to anions 
(9%, 0.2 mmol/l)
Nondiffusible protein-bound 
calcium (41%, 1.0 mmol/l)
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2.1.2 REGULATION OF CALCIUM HOMEOSTASIS 
 
Serum concentration and total body balance of calcium is kept within a narrow range 
by the interaction of calcium-sensing receptors and hormones (parathormone, 
vitamin D, calcitonin and FGF23). The organs taking part to the calcium 
homeostasis are parathyroid chief cells, thyroidal C-cells, and specific cell types in 
kidney, intestine, and bone. These mechanisms of calcium homeostasis are explained 
in the following sections and in Figure 2. 
 
 
    
 
Figure 2. Summary of the effects of parathyroid hormone on bone, the kidneys, and 
the intestine in response to decreased serum calcium concentration (adapted from 
Guyton and Hall, Textbook of Physiology 13th Edition) 
2.1.2.1 Parathormone 
Parathormone (PTH) is a peptide hormone which can rapidly regulate the calcium 
concentration in blood and extracellular fluid. The effect of PTH is mediated by PTH 
receptors expressed in bone, the kidneys, and the brain. The PTH receptors are found 
in both in osteoblasts and their precursors, but not in osteoclasts. PTH is first 
synthetized as a pre-pro-PTH. Mature PTH of 84 amino acids requires cleavage of 
25 amino acid pre- or signal sequence residues and of the six amino acid pro-
sequence residues. The mature PTH is packed into vesicles in the parathyroid chief 
cells and either secreted from the cell or sequestered in the cell. This 
carboxyterminal pro-PTH fragment, unlike the aminoterminal PTH fragments, is 
also secreted from the cell but does not activate PTH receptors. The half-life of PTH 
is two minutes, and it is degraded in the liver (70%) and kidneys (20%) (Marcocci, 
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Cetani 2011, Bilezikian et al. 2016, Fraser 2009, Bringhurst, F.R., Demay M.B., 
Kronenberg H.M 2008).  
The serum calcium level is the main regulator of PTH secretion, and its effect is 
mediated by the calcium-sensing receptors on parathyroid chief cells. Hypocalcemia 
leads to an increase in PTH secretion. PTH stimulates osteoclast resorption to release 
skeletal calcium, although this is mediated through osteoblasts. PTH also enhances 
calcium reabsorption from distal tubules and increases the turnover of 25-
hydroxyvitamin D to 1,25(OH)2D3. PTH also strongly inhibits phosphate and also 
renal sodium, water, and bicarbonate reabsorptions. PTH is a central regulation of 
bone formation and resorption (Brown 2013, Välimäki, Mäkitie 2009). 
2.1.2.2 Calcitonin, 1,25(OH)2D3 and FGF23 
Calcitonin is produced by the C-cells of the thyroid gland. This is stimulated by high 
serum calcium and is mediated by calcium-sensing receptors. Calcitonin reduces 
serum calcium by inhibiting osteoclasts and reduces calcium and phosphate release 
from bones (Fraser 2009).  
The active form of vitamin D is the 1,25(OH)2D3. Its main function is to provide 
the main minerals for bone by increasing the intestinal absorption of calcium and 
phosphate. The precursors of this form are either synthetized in the skin or received 
in the diet, especially in fish, margarine, and milk with vitamin D supplementation. 
The liver metabolizes these precursor forms to 25(OH)D3 which is converted later to 
1,25(OH)2D3 by 1α-hydroxylase in the kidneys. This latter step can be stimulated by 
PTH and hypophosphatemia. This active vitamin D increases the absorption of 
dietary calcium and phosphate in the gut, and decreases PTH formation (Figure 2). 
When dietary calcium is limited, PTH increases 1,25(OH)2D3 production and 
intestinal calcium absorption and mobilizes skeletal calcium (Brown 2013). Vitamin 
D is also important for muscle function (Välimäki, Mäkitie 2009). 
Fibroblast growth factor 23 (FGF23) is an important regulator of phosphate 
homeostasis. Its concentration in blood is increased when serum phosphate, serum 
calcium, or serum vitamin D concentrations or dietary intake of phosphate are high. 
FGF23 leads to hyperphosphaturia and a decrease in the production of 1,25(OH)2D3 
in the kidneys. When kidney function is impaired, FGF23 concentrations are higher. 
FGF23 is released at least from osteocytes, and the effect is mediated by its own 
receptor (Brown 2013, Välimäki, Mäkitie 2009).  
2.1.2.3 Calcium-sensing receptors 
Due to its critical role in the optimal functioning of the body, plasma calcium 
concentration is kept in a narrow range. It is monitored minute-to-minute and is 
closely regulated by calcium-sensing receptors (CaSR), which are G protein coupled 
receptors expressed in many tissues (Alfadda et al. 2014). CaSR senses small 
perturbations in plasma-ionized calcium from its normal level (Brown 2013). CaSRs 
mediate the alterations of calcium: in hypercalcemia, the secretion of PTH and 1,25 
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vitamin D is decreased and that of calcitonin is increased. CaSRs can also directly 
modulate the calcium reabsorption in kidneys to preserve normocalcemia. Some 
studies have found CaSRs on osteoclasts and osteoblasts (Brown 2013). In the 
stomach, CaSR stimulation by elevated ECF calcium concentration leads to 
increased gastrin secretion. CaSR influences fluid transport and motility in the colon, 




Figure 3. Effects of calcium-sensing receptors in different organs, adopted from Alfadda et al. 
2014 (Alfadda et al. 2014) 
2.1.3 EMBRYOGENESIS AND ANATOMY OF PARATHYROID GLANDS 
 
Healthy individuals usually have four parathyroid glands, two superior and two 
inferior, but supernumerary parathyroid glands can occur in 2–13% of the 
population. Approximately 1–3% have only three parathyroid glands. The superior 
parathyroids develop from the fourth pharyngeal pouch. The inferior glands develop 
from the third pouch and migrate a longer distance in conjunction with thymic tissue. 
Thus, these glands are more likely to be in ectopic sites (Duan, Gomez Hernandez & 
Mete 2015). 
The superior parathyroid glands can locate under the pseudocapsule of the 
thyroid gland or within the thyroid gland. A normal parathyroid gland appears 
brown, round-to-ovoid, small (often <6–8 mm), and can weigh up to 40–60 mg each 
(Duan, Gomez Hernandez & Mete 2015). Each gland has a thin fibrous capsule 
surrounding a network of adipose tissue, blood vessels, and glandular tissue. The 
parathyroid gland is composed predominantly of chief cells, as well as oncocytic 
cells, which are mitochondria rich, and rarely of clear cells (Carlson 2010, Bondeson 
et al. 2004). 




Figure 4. Anterior and posterior view of parathyroid glands with one enlarged gland, adopted from 
Harvard Health Publications. 
 
2.2 HISTORY AND EPIDEMIOLOGY OF PRIMARY 
HYPERPARATHYROIDISM 
2.2.1 HISTORY  
 
Primary hyperparathyroidism is an ancient disease with a 7000-year-old case, one of 
the earliest documented, described in a woman aged 25–35 discovered in an early 
Neolithic cemetery in Germany (Zink et al. 2005). The disease was confirmed by 
radiologic imaging showing changes consistent with HPT, including significant 
demineralization of the skeleton with a “salt and pepper” appearance of the skull. In 
1880, Swedish medical student Ivar Sandström was the first to describe the human 
parathyroid glands, whose function was unknown at that time, and he suggested the 
name “glandulae parathyroideae” (Carlson 2010). The first parathyroidectomy was 
performed by Dr. Felix Mandl in 1925 (Lee et al. 2016). 
2.2.2 EPIDEMIOLOGY 
 
The prevalence of PHPT is 1–4 cases in 1000 persons (Christensson et al. 1976, 
Boonstra, Jackson 1971), and it is most common among 55- to 75-year-old women 
(21 cases in 1000 persons) (Lundgren et al. 1997). According to a recent study, 
which included 3.5 million adults from the United States, the prevalence of PHPT 
tripled from 1995 to 2010, increasing from 76 to 233 per 100 000 women and from 
30 to 85 per 100 000 men (Yeh et al. 2013). The increase in prevalence is related to 
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conservatively treating patients with mild PHPT (Yeh et al. 2013). The reported 
incidence of PHPT has also increased in recent decades and is partly related to the 
introduction of the multichannel autoanalyzer in clinical laboratories (Bilezikian et 
al. 2016). In the United States, the incidence of PHPT is highest among blacks, 
followed by whites, Asians, and Hispanics (Yeh et al. 2013). 
2.3 PATHOGENESIS AND ETIOLOGICAL FACTORS OF 
THE PARATHYROID TUMORIGENESIS 
Abnormal parathyroid glands are associated with hypercalcemia in three settings: In 
PHPT, in familial hypocalciuric hypercalcemia (FHH), and in drug-induced 
hypercalcemia. Parathyroid adenoma causes 80–85%, multiglandular hyperplasia or 
double adenoma 10–15%, and parathyroid carcinoma 1–3% of PHPT cases 
(Bringhurst, F.R., Demay M.B., Kronenberg H.M 2008). It is very rare for PHPT to 
be caused by ectopic PTH secretion (Bilezikian et al. 2016).  
2.3.1 HEREDITARY SYNDROMIC FORMS OF PHPT 
 
Hereditary syndromic forms of PHPT include hyperparathyroidism-jaw tumor 
syndrome (HPT-JT), multiple endocrine neoplasia syndromes (MEN types 1 - 4), 
familial hypocalciuric hypercalcemia (FHH), and familial isolated HPT (FIHP). 
Recent data suggests that as many as 10% of younger patients (< 45 year of age) 
with apparent sporadic PHPT have a germline mutation in one of the genes 
associated with familial PHPT (Starker et al. 2012). A family history of 
nephrolithiasis or premature osteoporosis may be the first sign of a genetic basis for 
PHPT. Guidelines on genetic testing are presented in section 6.1. 
2.3.1.1 Hyperparathyroidism-jaw tumor syndrome (HPT-JT) 
HPT-JT is a rare, autosomal-dominant cancer syndrome caused by inactivating 
germline mutation of the tumor suppressor gene Cell Division Cycle 73 (CDC73), 
alternatively known as HRPT2, located on chromosome 1q25-32 (Newey et al. 
2010). Of the 17 exons in CDC73 gene, the most mutations are found from exons 1, 
2 and 7. It encodes a ubiquitously expressed protein, parafibromin, that is a 
transcriptional regulator as part of an RNA polymerase complex. CDC73 mutation 
leads to total absence of its protein product, parafibromin, which can be used as a 
diagnostic tool. More than a hundred CDC73 mutations have been found, two-thirds 
of them germline and other somatic mutations (Newey et al. 2010, Korpi-Hyovalti et 
al. 2014). CDC73 has an important role in the molecular pathogenesis of parathyroid 
carcinomas (PC) and a germline mutation is found in one-third of all PCs (Cetani, 
Pardi & Marcocci 2016).  
Because of the incomplete penetrance and variable expression of the CDC73 
mutation, patients with a germline CDC73 mutation (Bradley et al. 2006) present a 
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wide spectrum of phenotypes. The most common manifestation of HPT-JT is PHPT 
varying from familial isolated hyperparathyroidism (FIHP) to parathyroid cancer (in 
15% of PHPT in HPT-JT) including occasionally tumors in other organs (Korpi-
Hyovalti et al. 2014, Sharretts, Simonds 2010). These can be silent or clinically 
evident fibro-osseous tumors of the maxilla or mandible (histologically classified as 
cemento-ossifying fibromas), kidney tumors, such as Wilms tumor or cysts, and 
uterine lesions (Li, Simonds 2016). HPT-JT has no ethnic preference (Li, Simonds 
2016). 
2.3.1.2 Multiple endocrine neoplasia (MEN) syndromes 
MEN1 is a rare condition, with a prevalence of 2–3 per 100 000, but the most 
common of hereditary cause of PHPT accounting for 2% of all cases (Sharretts, 
Simonds 2010). Loss-of-function mutation in the tumor suppressor gene MEN1 
producing menin is responsible for autosomal-dominantly inherited MEN type 1. 
PHPT is the most common component of MEN1 with a 90% penetrance by the age 
of 50, typically presenting in the second to fourth decades of life. The disease is 
usually due to multiglandular hyperplasia and thus has a high rate of recurrence 
following apparent surgical cure. Malignant parathyroid tumors in MEN1 are rare 
(1–2% of all MEN1-related PHPT cases) (Christakis et al. 2016). MEN1 is also 
associated with pituitary and gastroenteropancreatic tumors, and less frequently with 
other tumors.  
Multiple endocrine neoplasia type 2 (MEN2) has three clinical variants: MEN2a, 
MEN2b (or MEN3) and MTC-only. Each type is associated with specific, 
autosomal-dominant, germline mutation in the RET (rearranged during transfection), 
a proto-oncogene that normally positively regulates cell growth and/or proliferation, 
but when activated by mutation can induce neoplasia. Patients with MEN2a, the 
most common, have medullary thyroid carcinoma (MTC) (99%), 
pheochromosytoma (50%) and parathyroid tumors (20%) of patients. PHPT is 
usually mild resembling a sporadic PHPT in its clinical presentation and is usually 
due to benign tumors (single or multigland disease). MEN2b is not associated with 
parathyroid tumors (Thakker 2016).  
Rarely, in 3%, patients with MEN1-associated tumors lack MEN1 mutation but 
have a mutation in CDKN1B. This gene encodes p27, a protein involved in cell cycle 
controlling (Marinoni, Pellegata 2011). This form is called multiple endocrine 
neoplasia type 4 (MEN4). These patients present with PHPT, pituitary, renal, or 
adrenal gland tumors, or with gastrointestinal neuroendocrine tumors, and the 
inheritance is autosomal dominant (Thakker 2016).  
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2.3.2 NON-SYNDROMIC FORMS OF PHPT 
2.3.2.1 Familial isolated hyperparathyroidism (FIHP) 
Familial isolated hyperparathyroidism (FIHP) is a clinically defined syndrome in 
relatives with HPT but which lacks the specific manifestations of other organs as in 
MEN1, HPT-JT or FHH. Some FIHP patients also have a germline mutation of 
MEN1, CDC73 or CaSR, suggesting incomplete penetrance (Simonds et al. 2004).  
2.3.2.2 Familial hypocalciuric hypercalcemia (FHH) 
FHH is an autosomal-dominant disorder with three subtypes with specific gene 
mutations, all leading to decreased sensitivity of CaSR to extracellular calcium 
concentration. Therefore, an increased level of ionized calcium is needed to suppress 
PTH secretion (Costa-Guda, Arnold 2014). FHH presents with a lifelong elevation in 
serum calcium concentration, normal PTH concentration, and in 80% of patients a 
low urinary calcium concentration (urinary calcium/creatinine ratio (CCR) < 0.01), 
and sometimes hypermagnesemia (Gorvin et al. 2016). These patients can be 
misdiagnosed as having PHPT, as 20% have elevated serum calcium and 20% may 
have CCR > 0.01. PHPT patients with vitamin D deficiency or renal insufficiency 
may also have low CCR. It is critical to diagnose FHH, as hypercalcemia is 
generally benign without skeletal or renal complication (Thakker 2016), and it 
parathyroidectomy does not correct hypercalcemia. Mutational analysis helps to 
distinguish FHH patients from those with PHPT.  
Patients with FHH1 have a heterozygous loss-of-function of the extracellular 
calcium-sensing receptor (CaSR) located in chromosome 3 (Hannan, Thakker 2013). 
FHH2 is related to the mutation of G protein subunit α11 (GNA11) (Gorvin et al. 
2016) and FHH3 to adaptor-related protein complex 2σ 1 subunit (AP2S1) (Nesbit et 
al. 2013). Both FHH2 and FHH3 are loss-of-function mutations in chromosome 19 
and represent on average 5% of FHH patients (Thakker 2016).  
Severe neonatal PHPT (NS-PHPT) is defined as symptomatic hypercalcemia 
with severe skeletal manifestations in the first six months of life (Thakker 2016). 
Homozygous CaSR mutations or the inheritance of two inactive CaSR alleles 
classically results in NS-PHPT (Costa-Guda, Arnold 2014, Gorvin et al. 2016). 
These children have life-threatening hypercalcemia during their first days or weeks 
of life and require urgent parathyroidectomy. 
2.3.3 TUMORIGENESIS IN SPORADIC ADENOMAS 
 
Parathyroid adenomas are monoclonal, caused by sequential mutations in the DNA 
of a parathyroid cell. It is now recognized that somatic mutations in the CCND1 
(PRAD1) oncogene, encoding cyclin D1 protein, and MEN1 tumor suppressor gene, 
encoding menin, are frequently found in sporadic parathyroid adenomas (Sharretts, 
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Simonds 2010). Acquired, inactivating mutation of both alleles of the MEN1 gene 
has been reported in 12–35% of sporadic parathyroid adenomas (Farnebo et al. 
1998). A pericentromeric inversion of chromosome 11 leads to the activation of 
transcription in CCND1 (PRAD1), and Cyclin D1 is overexpressed in 20–40% of 
sporadic adenomas. CCND1 mutations are found in 8% of cases (Costa-Guda, 
Arnold 2014). However, hyperplastic parathyroid glands are of polyclonal origin and 
are related to hereditary forms of PHPT (see section 4.1) (Costa-Guda, Arnold 
2014). Somatic inactivation of CaSR has not been found in sporadic parathyroid 
adenomas (Hosokawa et al. 1995), and inactivating germline mutations of CaSR in 
sporadic adenoma patients are very rare, detected in <1% of patients (Guarnieri et al. 
2010). 
The incidence of PHPT among those who received radiation to tonsils before the 
age of 16 was 18.7 per 100 000 person-years below the age of 40 and 171 per 
100,000 person-years in the age range of 40 to 60 years, representing a 2.9-fold and 
2.5-fold increase compared with that among the general population (Cohen, 
Gierlowski & Schneider 1990). 
2.3.4 LITHIUM-INDUCED PHPT  
 
On average, 10% of patients on lithium therapy, serum calcium and PTH 
concentrations are elevated (McKnight et al. 2012). Lithium inactivates the CaSR, 
leading to an increased release of PTH (McKnight et al. 2012). Hypercalcemia is 
often reversible within several months after stopping lithium therapy, but 
occasionally hypercalcemia persists. In these cases, surgery reveals a parathyroid 
adenoma (in 92% of cases) or a four-gland hyperplasia (Awad, Miskulin & 
Thompson 2003, Szalat, Mazeh & Freund 2009). Of all lithium users, the risk for 
hypercalcemia was highest in women over the age of 60 and lowest in young men 
(Shine et al. 2015). Serum calcium should be measured when starting lithium 
therapy and it should be checked annually during the treatment.  
2.4 HISTOPATHOLOGY OF PARATHYROID TUMORS 
2.4.1 PARATHYROID ADENOMA 
 
The average weight of adenomas weight 1 g, whereas the normal parathyroid gland 
weight is approximately 40–60 mg (DeLellis 2011). Parathyroid adenomas are 
benign neoplasms composed of varying proportions of chief, oncosytic, transitional 
oncocytic, and clear cells (Duan, Gomez Hernandez & Mete 2015). Adenomas are 
encapsulated and often have a rim of normal parathyroid in the periphery. The cells 
are arranged in different proportions of cords, nests, sheets, and follicles mimicking 
thyroid tissue (Duan, Gomez Hernandez & Mete 2015). Cystic changes are relatively 
common in large adenomas (DeLellis 2011). A mitotic figure can be present, but the 
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proliferation index (PI) is usually < 4% (Duan, Gomez Hernandez & Mete 2015, 
Abbona et al. 1995). The parathyroid adenoma cells stain positively for cytokeratins, 
PTH, and chromogranin A, while staining for thyroglobulin and thyroid transcription 
factor-1 (TTF1) is negative (DeLellis 2011). Immunohistochemical stainings are 
used to distinguish parathyroid from thyroid tissue. PTH staining is positive in 
parathyroid tissue, and thyreoglobulin or TTF1 are positives in thyroid tissue 
(Grimelius et al. 2004).  
2.4.2 PARATHYROID HYPERPLASIA 
 
Parathyroid hyperplasia is a multiglandular disorder with morphological variants of 
diffuse, nodular hyperplasia (with one or more nodules) and a mixture of these 
(Duan, Gomez Hernandez & Mete 2015). In PHPT caused by hyperplasia, 25% of 
cases are heritable (as with MEN types 1–4). In hyperplastic glands, chief cells 
dominate, the ratio of parenchymal cells to fat is increased and, as in adenomas, a 
rim of normocellular parathyroid tissue can be found at the periphery. 
When two or more parathyroid glands are enlarged, parathyroid hyperplasia 
should be considered in differential diagnosis. Diagnosis cannot solely be based on 
histological criteria, as parathyroid glands in chief cell hyperplasia may have a 
similar appearance to that of small adenomas. The examination of associated glands 
left in situ is important to distinguish hyperplastic glands from adenomas. Strong 
nuclear pleomorphism suggests a parathyroid adenoma instead of hyperplasia. The 
glands are symmetrically enlarged in ~50% of the cases (DeLellis 2011, Grimelius et 
al. 2004).  
2.4.3 ATYPICAL PARATHYROID ADENOMA  
 
Atypical parathyroid adenomas (APA) are borderline neoplasms and often larger 
than adenomas but smaller than PCs. They share some features of PC such as 
fibrosis, hemosiderin deposits, and mitoses, but, importantly, they lack definitive 
evidence of invasive growth (Duan, Gomez Hernandez & Mete 2015, Bondeson et 
al. 2004). Adherence to surrounding tissue is not as common as in PC (Schneider et 
al. 2015, Quinn et al. 2015).  
2.4.4 PARATHYROID CARCINOMA 
 
Malignant parathyroid tumors present as larger masses that are often adherent to 
adjacent structures. Compared to adenomas, carcinomas are gray-white and have a 
firmer consistency. The World Health Organization (WHO) criteria for parathyroid 
carcinoma include vascular invasion, invasion to perineural space, capsular 
penetration with growth to adjacent tissue, and/or metastases (Bondeson et al. 2004). 
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Vascular invasion should be present in the tumor capsule or in the surrounding tissue 
rather than within the tumor. The frozen section is of little value in distinguishing 
benign from malignant disease, and thin-needle biopsy that can cause tumor cell 
seeding is strongly discouraged and gives little information on possible tumor 
invasion (Cetani, Pardi & Marcocci 2016). Parathyroid carcinoma is characterized 
by recurrent local disease and typically metastases to cervical and mediastinal lymph 
nodes. Local recurrences are highly suspicious for malignancy, but local seeding 
from intraoperatively ruptured adenoma can implant and mimic malignant growth 
(parathyreomatosis) (Bondeson et al. 2004, Fernandez-Ranvier et al. 2007). Distant 
metastases are found most commonly in lungs, but also in bone and liver. Bone 
metastases should be distinguished from Brown tumors related to severe PHPT and 
cemento-ossifying fibromas in mandible and maxilla related to hereditary 
parathyroidism-jaw tumor syndrome (HPT-JT) (Cetani, Pardi & Marcocci 2016).  
In carcinomas, chief cells predominate, but oncocytic tumors occur, and mixtures 
of the cells are seen. Oncocytic carcinomas seem to share similar clinical behavior 
with carcinomas composed of chief cells. Band-forming fibrosis and hemosiderin 
deposits are common but not pathognomonic findings in PC (Bondeson et al. 2004, 
Fernandez-Ranvier et al. 2007). The triad of coagulative necrosis, macronucleoli, 
and Ki-67 over 10% strongly suggest malignant parathyroid tumors (Bondeson et al. 
2004, Fernandez-Ranvier et al. 2007). 
2.4.5 IMMUNOHISTOCHEMISTRY IN PARATHYROID TUMORS 
 
Differentiating benign and malignant parathyroid tumors is often challenging, as 
invasive growth is not always unequivocal and tumors are enucleated with very 
small margins. Many immunohistochemical markers, such as parafibromin, 
retinoblastoma protein, PGP9.5, Ki-67, cyclin D1, and galectin-3 have been studied 
to distinguish between benign and malignant parathyroid tumors.  
Parafibromin (PF), the protein product of CDC73, is present in nearly all 
adenomas, absent in 31–38% of PCs, and in 21% of atypical adenomas (Quinn et al. 
2015, Fernandez-Ranvier et al. 2007). The mutation in CDC73 leads to the absence 
of PF in parathyroid tissue. A recent study reported that PF-negative APAs did recur 
in 10% of cases in contrast to PF-positive APAs, none of which recurred (Kruijff et 
al. 2014). The proliferation marker Ki-67 levels may be increased both in benign and 
malignant tumors, and do not have diagnostic value in this respect. However, indices 
greater than 5% should lead to a closer and prolonged follow-up of the patients due 
to increased risk of malignancy and recurrence (Bondeson et al. 2004). Quinn et al. 
reported PI of 6.8% vs 3.9% for PCs vs APAs (Quinn et al. 2015). Some studies 
suggest immunohistochemical panels to be superior compared to any single marker 
(Fernandez-Ranvier et al. 2007, Truran et al. 2014). It has been suggested that E-





2.5 CLINICAL PRESENTATION 
2.5.1 THE CHANGING PRESENTATION OF PHPT 
 
The classical presentation of PHPT, also described as “painful bones, renal stones, 
abdominal groans and psychic moans” includes skeletal and renal involvements as 
well as symptoms related to hypercalcemia (Bilezikian et al. 2016). PHPT is also 
associated with hypertension and with other cardiovascular changes. In Western 
countries, the detection of serum calcium levels as part of many routine screenings 
has increased diagnoses of PHPT and especially of the mild forms of the disease. In 
developing countries, the classic PHPT still dominates: in Beijing, China, the mean 
age of PHPT patients is 37 years, 60% having the bone involvement of the disease 
(Bilezikian et al. 2000).  
The primary abnormality of parathyroid tissue leads to inappropriate secretion of 
PTH. This is succeeded by excessive tubular calcium reabsorption and phosphaturia, 
1,25(OH)2 D synthesis in kidneys, and increased bone resorption, resulting in 
hypercalcemia and hypophosphatemia and cortical bone loss (Bringhurst, F.R., 
Demay M.B., Kronenberg H.M 2008). However, when PHPT patients develop 
hypercalciuria, the amount of urinary calcium exceeds the ability of PTH to enhance 
tubular calcium reabsorption (Bilezikian et al. 2016). 
2.5.2 SKELETAL INVOLVEMENT OF PHPT 
 
Specific skeletal manifestations of PHPT, called osteitis fibrosa cystica, are seen in 
advanced forms of PHPT. The symptoms include bone pain, skeletal deformities, 
and pathological fractures (Bilezikian et al. 2016), and are due to the generalized 
increase in bone resorption and osteoblastic activity (Bringhurst, F.R., Demay M.B., 
Kronenberg H.M 2008). Generalized demineralization of bone is evident as 
subperiosteal bone resorption, especially in the phalanges of the hands, and as bone 
cysts and brown tumors, composed of multinucleated osteoclasts, stromal cells and 
matrix, most often found in trabecular parts of the jaw, the long bones and the ribs. 
The skull often presents with a salt and pepper appearance in radiologic imaging 
(Bringhurst, F.R., Demay M.B., Kronenberg H.M 2008).  
In mild PHPT, the bone involvement is typically seen only as a decrease in bone 
mineral density assessed by Dual X-ray Absorptiometry (DXA). It is known that the 
cortical bone compartment is especially involved. In an Italian cohort of 
consecutively diagnosed PHPT patients, 63% had a T-score < -2.5 SD at any site in 
DXA and 35% had a vertebral fracture (> 25% in height of a vertebra) according to 
X-rays (Cipriani et al. 2015). Vestergaard et al. noticed an increase in the bone 
fracture risk as early as 10 years before parathyroidectomy in PHPT patients 
(Vestergaard et al. 2000). According to a recent study (Castellano et al. 2016), 11% 
of patients with no symptoms, bone or renal signs of PHPT had osteoporosis (T-
score ≤ -2.5 SD), and half of these met the criteria for parathyroidectomy.  
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However, bone mineral density accounts for only approximately 60–80% of the 
reduction in bone strength. The Trabecular Bone Score (TBS) assessment and high-
resolution peripheral quantitative CT (HRpQCT) have been used to assess bone 
quality in PHPT (Silva et al. 2013, Stein et al. 2013). Measuring bone density in the 
hip, lumbar spine, and the distal third of the radius is recommended in the evaluation 
of PHPT. A vertebral fracture in an X-ray or computed tomography (CT) (regardless 
of bone mineral density) or an osteoporotic value (T-score < -2.5 SD) in the lumbar 
spine, total hip, or distal third of the radius in DXA are considered to be criteria for 
parathyroidectomy (Bilezikian et al. 2014). After surgery, fracture risk seems to 
return to the same level as in age- and gender-matched controls (Vestergaard et al. 
2000). The fracture risk of those not operated on remains increased (Vestergaard, 
Mosekilde 2003a). 
2.5.3  RENAL INVOLVEMENT OF PHPT 
 
In the kidneys, PTH stimulates the renal tubular reabsorption of calcium. However, 
in spite of this, total renal calcium excretion is typically increased due to the 
augmented filtered calcium load (Starup-Linde et al. 2012). Renal stones can be 
asymptomatic or may cause acute, intermittent flank pain radiating to the lower 
abdominal groin, as well as hematuria and nausea. 
Renal manifestations in severe PHPT include recurrent renal stones (stones in the 
urinary tract), nephrocalcinosis, and renal function abnormalities ranging from 
impaired renal concentration capacity to end-stage renal failure (Bilezikian et al. 
2016). Fifty years ago, the prevalence of renal stones was 60%, but is estimated to 
now be around 7–20% (Bilezikian et al. 2016, Mollerup et al. 2002). The prevalence 
of PHPT among patients presenting with nephrolithiasis is 2–8% (Mollerup et al. 
2002). In a Danish cohort of operated PHPT patients, the prevalence of renal 
calcification was 25.4% (15.3% having renal stones and/or 10.3% renal 
calcifications) in CT imaging (Starup-Linde et al. 2012).  
Hypercalciuria is generally considered to be a contributor to the pathophysiology 
of nephrolithiasis, but the precise relationship between PHPT and nephrolithiasis is 
incompletely understood (Rejnmark, Vestergaard & Mosekilde 2011). Calcium 
phosphate stones predominate, but calcium oxalate and mixed calcium stones are 
also common, whereas uric-acid stones are less common (Rejnmark, Vestergaard & 
Mosekilde 2011). Most studies (Starup-Linde et al. 2012, Mollerup et al. 2002, 
Rejnmark, Vestergaard & Mosekilde 2011, Berger et al. 2009) have not found any 
correlation between renal calcium excretion and kidney stones. There were no 
significant differences in urine analysis between PHPT patients with and without 
kidney stones (Berger et al. 2009). According to a large meta-analysis by Mollerup 
et al. (Mollerup et al. 2002), the risk of renal stones is increased in males and at 
young onset age of PHPT, whereas the risk is not increased in users of oral calcium 
supplements. The risk of nephrolithiasis has been shown to decrease after curative 
parathyroidectomy (PTX), although the risk remains slightly increased compared 
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with the background population (Rejnmark, Vestergaard & Mosekilde 2011). The 
risk decreases to near-normal after a 10-year follow-up (Mollerup et al. 2002). 
PHPT associates with renal impairment in severe forms of PHPT but, according 
to a large recent review of the literature (Hendrickson, Castro Pereira & Comi 2014), 
it is not commonly observed in mild PHPT. Patients with concomitant renal disease 
or any renal impairment are thought to be more prone to PHPT-mediated kidney 
damage and nephrocalcinosis (Hendrickson, Castro Pereira & Comi 2014). Older 
studies (Kristoffersson et al. 1990) have reported an improvement in renal 
concentration capacity, but no change in GFR after a one-year follow-up. A study of 
109 consecutive patients operated on for PHPT, including 14 subjects with reduced 
GFR, demonstrated no change in GFR after parathyroidectomy (Tassone et al. 
2015). In the three randomized studies comparing observed and surgically-treated 
mild PHPT patients not fulfilling the current surgical criteria (Ambrogini et al. 2007, 
Bollerslev et al. 2007, Rao et al. 2004), there were no changes in pre- and 
postoperative creatinine levels at 1–2-year follow-up. Accordingly, the surgical 
criteria recommending operations for all with GFR < 60ml/min/1.73 m2 have been 
also criticized (Hendrickson, Castro Pereira & Comi 2014, Tassone et al. 2015, 
Walker et al. 2014). 
2.5.4 MUSCULAR AND NEUROLOGICAL MANIFESTATIONS IN PHPT  
 
Non-specific symptoms associated with PHPT include reduced muscle strength, 
neurocognitive symptoms (fatigue, depression, and memory loss), reduced well-
being, polydipsia, abdominal pain, nausea and constipation, as well as non-specific 
pain in the back and extremities.  
Classical, severe PHPT has been associated with weakness and easy fatigability 
of muscles. Muscle biopsies showed atrophy of both type I and type II muscle fibers, 
and electromyogram (EMG) was abnormal, especially in lower extremities in PHPT 
patients whose symptoms ameliorated after parathyroidectomy (Patten et al. 1974). 
In mild PHPT, neuromuscular disease is rare and neurological examination remains 
normal, but weakness and easy fatigability are common complaints (Bilezikian et al. 
2016). PHPT patients demonstrated alterations in EMG with a subclinical sensory-
motor peripheral polyneuropathy compared to healthy persons (Diniz et al. 2013). 
Mechanisms of action accounting for muscle weakness and neurocognitive 
symptoms seem to include increased plasma Ca2+ hampering muscle contraction 
(Rolighed et al. 2014b). PTH receptors are also found in brain and muscle tissues, 
which can be related to the mechanisms in neurological and muscle symptoms 
(Reppe et al. 2007). In PHPT, the reduced muscle function improves to the level of 
the control group after surgery (Deutch et al. 2000). In addition, asymptomatic 
patients have reduced muscle function (Rolighed et al. 2014a).  
Neurocognitive skills, such as concentration, nonverbal learning, and memory, 
are also impaired in PHPT, and neuropsychiatric alterations (anxiety and mood) are 
evident in PHPT (Babinska et al. 2012, Walker et al. 2009, Roman et al. 2011b). 
Improvement in these symptoms have been reported after parathyroidectomy in 
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prospective, case control studies (Babinska et al. 2012, Walker et al. 2009, Roman et 
al. 2011b, Weber et al. 2013).  
2.5.5 CARDIOVASCULAR HEALTH IN PHPT 
 
Hypertension, premature atherosclerosis, valve calcification, left ventricular 
hypertrophy, and arrhythmias have been associated with PHPT (Iwata et al. 2012). A 
large meta-analysis (van Ballegooijen et al. 2013) demonstrates that higher PTH 
concentration is associated with increased risk of fatal and non-fatal cardiovascular 
events. PTH receptors have been found in cardiomyocytes, and left ventricular 
dysfunction is related to PHPT. According to another large meta-analysis, 
parathyroidectomy has a beneficial effect on cardiovascular events, while the 
magnitude of the effect depends on the preoperative PTH level (Walker et al. 2012). 
Mild PHPT is also associated with aortic valve calcification, and PTH is an 
important predictor of the valve calcification (Iwata et al. 2012).  
There is also growing evidence of a bidirectional relationship between the renin-
angiotensin-aldosterone system (RAAS) and PTH. Both serum aldosterone and PTH 
concentrations has been reported to decrease during RAAS inhibitor treatment 
(Brown et al. 2015). Patients with primary hyperaldosteronism have higher PTH 
levels than those with essential hypertension, and both adrenalectomy or 
spironolactone decreases PTH concentrations (Pilz et al. 2012). The aldosterone-
renin ratio is independently associated with nocturnal blood pressure in PHPT 
patients and is related to the severity of the disease (Verheyen et al. 2016). Primary 
aldosterone is associated with lower BMD and a higher fracture risk (Vaidya, Brown 
& Williams 2015).  
2.5.6 QUALITY OF LIFE IN PHPT 
2.5.6.1 Assessing health-related quality of life  
The concept of health-related quality of life (HRQoL) has evolved since the 1980s. 
The World Health Organization’s (WHO) definition of health includes mental, 
physical, and social aspects. The WHO’s International Classification of Functioning, 
Disability and Health (ICF), a classification of health and health-related domains, 
describes the different aspects related to HRQoL (Sintonen 2013). HRQoL also 
includes the patient’s perception of his/her physical and mental health. There is no 
gold standard or reference ranges for HRQoL, thus the results need to be compared 
to pretreatment values or a control group (Sintonen 2001). 
HRQoL can be measured by disease-specific or generic methods. Disease-
specific instruments are designed for specific patient populations. Of these, the PAS 
(Pasieka’s Assessment Score) (Pasieka et al. 2002) and the disease-specific HRQoL 
questionnaire for PHPT patients called the PHPQoL-16 (Webb et al. 2016) have 
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been designed for PHPT. Generic methods measure HRQoL and its changes, and are 
appropriate to all patients regardless of the disease. Generic instruments provide a 
comparison between different patient groups. HRQoL is affected by patients’ gender 
and age distribution (Sintonen 2013). In PHPT patients, Short Forms (SF)-36 has 
been most commonly used. 
An HRQoL instrument can give one score and/or a profile. The Finnish 15-
dimensional questionnaire (the 15-D instrument) is a well-validated, generic, self-
administered measure for HRQoL. It can be used as a single score or as a profile of 
15 different dimensions (mobility, vision, hearing, breathing, sleeping, eating, 
speech, excretion, usual activities, mental function, discomfort and symptoms, 
depression, distress, vitality, and sexual activity) presented as a graph. It consists of 
15 questions and it is completed in four minutes on average (see Appendix 1 and 2) 
(Sintonen 2001). The 15D covers 80% of the domains of ICF, and the sensitivity in 
reacting to changes after an intervention is among the best of all the HRQoL 
instruments (Saarni et al. 2006, Kontodimopoulos et al. 2012).  
Short Form-36 (SF-36) is a generic general health survey (Jenkinson, Coulter & 
Wright 1993). The questionnaire assesses 36 items and consists of eight dimensions: 
Social and physical functioning, mental health, physical and mental role limitation, 
vitality/energy, pain, and general health perception. It provides two scores: One for 
mental and one for physical components, as well as scores for all dimensions. It has 
been widely used in HRQoL of PHPT. 
2.5.6.2 Health-related quality of life in PHPT 
Health-related quality of life is often reduced by chronic diseases such as PHPT. 
Adequate tools are needed for assessment of the prevalence of neurocognitive 
symptoms and their impact on daily life in PHPT. The transition of PHPT toward 
mild or even asymptomatic disease has led to a need to re-evaluate the effects of the 
disease on patients, as well as the surgical criteria (Grant, Velusamy 2014).  
There is a consensus that HRQoL is reduced in PHPT (Pasieka et al. 2002, 
Burney et al. 1999), and in mild PHPT patients not fulfilling the international criteria 
for surgery when compared to controls (Bollerslev et al. 2007) or to thyroid-operated 
patients (Weber et al. 2013, Pasieka et al. 2002).  
In patients operated on because of PHPT according to the prevailing surgical 
criteria, an improvement in HRQoL was observed (Burney et al. 1999, Blanchard et 
al. 2014, Caillard et al. 2007, Gopinath, Sadler & Mihai 2010, Sheldon et al. 2002). 
Of three prospective, randomized studies evaluating mild PHPT patients not 
fulfilling the surgical criteria, a significant improvement in HRQoL was reported: 
Two cohorts of patients aged 53–56(Ambrogini et al. 2007, Rao et al. 2004) reported 
significant changes as assessed by the SF-36. The largest study of 191 patients by 
Bollerslev et al. (Bollerslev et al. 2007) demonstrated reduced preoperative HRQoL, 
but failed to find a significant increase in HRQoL after parathyroidectomy. 
However, there were some patients who did not accept the result of randomization 
and changed group from the surgery to the follow-up group. A recent meta-analysis 
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(Cheng et al. 2015) concluded that HRQoL might improve in patients with 
asymptomatic PHPT after parathyroidectomy. 
Some (Weber et al. 2013, Blanchard et al. 2014) but not all (Burney et al. 1999, 
Blanchard et al. 2014, Caillard et al. 2007, Gopinath, Sadler & Mihai 2010, Sheldon 
et al. 2002) studies found a correlation between serum calcium levels and 
postoperative improvement of HRQoL. The Fourth International Workshop on 
PHPT in 2014 (Silverberg et al. 2014) concluded that PHPT is associated with 
reduced HRQoL but that the data from randomized controlled trials is inconsistent 
regarding the benefits of parathyroidectomy on neurocognitive symptoms in mild 
PHPT.  
2.5.7 MORTALITY IN PHPT 
 
A Danish study reported higher mortality for conservatively-treated compared to 
surgically-treated PHPT patients with a mortality of 37% and 31%, respectively, in a 
6-year follow-up (Vestergaard, Mosekilde 2003b).  
2.5.8 NORMOCALCEMIC PHPT  
 
Before the diagnosis of normocalcemic PHPT (NPHPT) can be made, secondary 
hyperparathyroidism should be excluded, and calcium and PTH concentrations 
should be measured on several occasions (Eastell et al. 2014). Causes of secondary 
hyperparathyroidism include vitamin D deficiency (minimal 25OH D level > 50 
nmol/l), low calcium intake related to bariatic surgery or malabsorptive conditions 
such as untreated celiac disease, hypercalciuria or renal failure, or drugs known to 
increase PTH concentration (hydrochlorothiazides, anticonvulsants, lithium, and 
bone resorption inhibitors (denosumab or bisphosphonates). After successful surgery 
for PHPT, normocalcemia with transiently elevated PTH can be seen in patients with 
skeletal involvement (Bilezikian et al. 2016). It has been proposed that NPHPT is an 
early phase preceding PHPT (Eastell et al. 2014). A recent study comparing the 
change in bone mineral density (BMD) after parathyroidectomy in normo- and 
hypercalcemic patients with PHPT also reported a significant increase in the NPHPT 
group (Koumakis et al. 2013). 
2.6 EVALUATION 
The evaluation of hypercalcemic patients starts with a carefully performed medical 
history and physical examination. The history must include previous neck operations 
and exposure to radiation, family history regarding calcium metabolism and tumors 
in endocrine or other organs, previous bone fractures or symptoms of renal stones, 
and medication. Neurocognitive and other symptoms should be evaluated. On 
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physical examination, attention should be paid to palpation of the neck and to 
assessing possible problems with the voice (Marcocci, Cetani 2011).  
2.6.1 BIOCHEMISTRY 
 
The diagnostic criteria of PHPT include hypercalcemia that has sustained for 3–6 
months in combination with increased PTH concentration. Calcium can be measured 
in serum either as albumin-adjusted calcium or ionized calcium concentration. 
Second-generation PTH assays measure with two antibodies (1-84) PTH and also 7–
84 fragments, but there are also third-generation assays recognizing the extreme N-
terminal fragment (1-4) of PTH, the measurement of which is recommended. In 
some rare cases, hypercalcemia is due to PHPT, although PTH concentrations 
remain within normal range (Marcocci, Cetani 2011, Bilezikian et al. 2016). 
In the evaluation of a patient with PHPT, serum 25-hydroxy-vitamin D, often 
decreased in PHPT, and renal function should be measured. In addition, the 24-hour 
urine calcium and creatinine levels should be investigated and the calcium/creatinine 
clearance ratio < 0.01 suggests FHH. Serum phosphate is often decreased in PHPT. 
The bone turnover marker, urinary N-telopeptide of type 1 collagen (U-NTX), and 
the bone formation markers serum alkaline phosphatase and serum procollagen type 
I N-propeptide (S- PINP) may be increased in patients with skeletal involvement 
(Marcocci, Cetani 2011, Bilezikian et al. 2016, Fraser 2009, Bringhurst, F.R., 
Demay M.B., Kronenberg H.M 2008). Genetic screening for CDC73, MEN1, and 
RET genes, for instance, is indicated in high-risk patients (Udelsman et al. 2014); 
these are those with PHPT occurring before the age of 45, with multigland disease, 
with atypical adenoma or parathyroid carcinoma, the first degree relatives of 
mutation carriers, and patients with at least two MEN-syndrome-associated 
endocrine tumors (Thakker 2016).  
2.6.2 IMAGING  
 
DXA from the lumbar spine, hip and distal third of the radius site and an X-ray of 
the spine or vertebrae fracture assessment (VFA) are recommended in order to 
evaluate the skeletal involvement of PHPT. If available, other methods such as the 
Trabecular Bone Score by DXA can give additional information on bone quality. If 
24-hour urinary calcium exceeds 10 mmol (400 mg), further imaging with 
ultrasound, X-ray, or CT should be performed to assess renal involvement 
(Marcocci, Cetani 2011, Bilezikian et al. 2016). 
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2.6.3 CRITERIA FOR SURGERY 
 
The international guidelines in PHPT for parathyroidectomy were re-evaluated and 
reported by the Fourth International Workshop on the Management of 
Asymptomatic PHPT in 2014 (Udelsman et al. 2014). According to these guidelines, 
surgery is recommended for all patients under 50 years of age, or when serum 
calcium is ≥ 0.25 mmol/l above normal. The presence of a vertebrae fracture 
detected by DXA, X-ray, or VFA, or osteoporosis (T-score (Z-score in men and 
premenopausal women) < -2.5 SD in the lumbar spine, total hip, femoral neck, or 
distal third of radius in DXA) is an indication for parathyroidectomy. Renal changes 
requiring surgical care are creatinine clearance < 60 ml/min and presence of 
nephrocalcinosis or nephrolithiasis in an ultrasound, X-ray or CT. In addition, 
patients planning a pregnancy are guided to operation. Patients with NPHPT and 
osteoporosis, kidney stones, and nephrocalcinosis need parathyroidectomy, and for 
those not operated on, annual calcium and PTH measurements are recommended 
(Bilezikian et al. 2014). The surgical criteria of the Third International Workshop on 
the Management of Asymptomatic PHPT that were in use between 2008 and 2014 
also included hypercalciuria ( > 10 mmol/ 24 h) (Udelsman et al. 2009b). In the 
Helsinki and Uusimaa Hospital District, parathyroidectomy is recommended to 
individuals with PHPT and one of following criteria: age < 50 years, serum ionized 
calcium over 1.50 mmol/l, serum ionized calcium over 1.40 mmol/l, impaired renal 
function, or a decrease of >30% in the glomerular filtration rate or a history of renal 
stones, osteoporosis, or an osteoporotic fracture, and an unquestionable PHPT with a 
1–2 year history of neuropsychiatric symptoms (Välimäki, Mäkitie 2009). 
2.7 PREOPERATIVE IMAGING 
In PHPT, preoperative imaging should not be used as a diagnostic procedure, and 
should be performed only on patients scheduled for surgery (Udelsman et al. 2014). 
Neck ultrasound and parathyroid scintigraphy are the most commonly used 
preoperative imaging techniques (Udelsman et al. 2014). Preoperative imaging may 
identify ectopically located abnormal parathyroid glands, and will guide the surgeon 
in terms of the type of surgery that should be chosen (bilateral neck exploration or 
minimally invasive surgery) (Schildt et al. 2015). It has been estimated that 60–70% 
of parathyroidectomies for PHPT could be unilateral or targeted operations, but this 
requires an unequivocal finding from preoperative imaging. Imaging methods tend to 
be false negative in multiglandular disease (MGD), the rate of which has been 
estimated at 15% of PHPT cases (Berber et al. 2008). 
2.7.1 ULTRASOUND  
 
Ultrasound (US) is one of the most commonly used imaging methods before 
parathyroidectomy in PHPT. Most surgeons appreciate US as it evaluates the size of 
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the thyroid gland in general, and is good for identifying thyroid nodules (Schildt et 
al. 2015). Ultrasound is a low-cost, noninvasive method, and it does not expose the 
patient to ionizing radiation (Udelsman et al. 2014).  
A meta-analysis by Cheung et al. (Cheung et al. 2012) of selected imaging 
studies published between 1997 and 2009 reported a mean preoperative US 
sensitivity of 76% (range 43% - 96%), and positive predictive value (PPV) of 93% in 
PHPT patients operated on for the first time. In a review of studies including all 
together 20,000 PHPT patients, the sensitivity of US for MGD was 35% (Ruda, 
Hollenbeak & Stack 2005). Another review for studies published between 1995 -
2003, including also reoperated patients, reported a sensitivity of 78% for US and 
only 5.7% for patients having multiglandular disease (Ruda, Hollenbeak & Stack 
2005). Multiglandular disease and concomitant thyroid disease, such as goiter and 
thyroid nodules, also reduce the sensitivity of US (Medas et al. 2016). Ultrasound is 
of limited value in evaluating retroesophageal lesions as it can not penetrate the 
clavicles or sternum. The evaluation of mediastinal parathyroid glands is therefore 
quite limited. US is also highly performer-dependent (Schildt et al. 2015). 
2.7.2 SCINTIGRAPHY 
2.7.2.1 Planar single- and double-tracer 99mTechnetium-
scintigraphies 
99mTechnetium-multiplex ion-beam imaging (99mTc-MIBI) was first introduced by 
Coakley et al. in 1989 (Coakley et al. 1989). Sestamibi is a lipophilic cation that 
accumulates in the mitochondria due to the transmembrane electrical potential. 
Normal parathyroid glands are not visible in sestamibi images. 99mTechnetium-
sestamibi is sequestered into mitochondria in the thyroid and parathyroid glands as 
well as in salivary glands and cardiac cell muscle.  
Dual-phase 99mTc-MIBI scintigraphy, where imaging is performed twice every 
few minutes as well as two hours after the injection of the tracer, is based on 
different washout times in the tissues taking up 99mTechnetium. Maximum thyroid 
activity is reached within five minutes after the injection. In contrast, washout in the 
parathyroid tissue is delayed, which allows parathyroid imaging two hours later 
(Greenspan et al. 2012). A disadvantage of this protocol is false positives due to 
thyroid nodules, and some parathyroid tumors may show a rapid washout and give a 
false negative result (Jorna et al. 2007). Imaging performed with a gamma camera is 
2-dimensional. Parallel, pinhole, or all-purpose collimators can be used for this 
imaging, and pinhole collimators are considered to be superior to parallel collimators 
(Klingensmith et al. 2013, Tunninen et al. 2013). 
In double-tracer scintigraphy, a thyroid-specific isotope 123Iodine or 99mTc-
pertechnetate is used together with 99mTc-MIBI. The thyroid images are digitally 
subtracted from the 99mTechnetium images. This method can be performed as a dual-
phase protocol, or with early/late images only. Some studies report that the late 
phase images do not bring any further information (Caveny et al. 2012, Chen et al. 
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1997). Most studies comparing planar dual-phase 99mTc-MIBI and 99mTc-MIBI-
subtraction with iodine or pertechnetate have found the sensitivity of the double-
tracer method to be superior to 99mTc-MIBI alone (72–94% versus 62–79%) (Caveny 
et al. 2012, Chen et al. 1997, Hindie et al. 1998, Leslie et al. 2002). However, a 
study with only 11 cases with a dual-tracer scintigraphy (Jorna et al. 2007) did not 
report any benefit of adding 123Iodine-subtraction to 99mTc-MIBI scanning. In 2009, 
the European Association of Nuclear Medicine (EANM) recommended the use of 
thyroid-specific isotope over 99mTechnetium imaging alone for parathyroid imaging 
(Hindie et al. 2009), and this was also the conclusion of a recent review (Hindie et al. 
2015). 
Multiglandular disease. Localizing multiglandular glands is challenging both for 
99mTc-MIBI and 123Iodine/99mTc-MIBI scans. Ruda et al. pooled the results for 
sestamibi scintigraphy from 215 studies and concluded that the sensitivity for a 
single adenoma is 88%, for MGD 45% and for double adenomas 30% (Ruda, 
Hollenbeak & Stack 2005). Studied by Jorna et al. (Jorna et al. 2007), in the 
subgroup of multiglandular disease, 99m Tc-MIBI scintigraphy had a sensitivity of 
47% and a PPV of 95%, 99mTc-MIBI SPECT and 123Iodine/99mTc-MIBI had 
sensitivities and PPV of 44/10% and 52/92%, respectively. 
2.7.2.2 99mTechnetium-single-photon emission computed 
tomography/computed tomography (SPECT/CT) 
Comparison of planar 99mTc-MIBI, 99mTc-MIBI SPECT and 99mTc-MIBI SPECT/CT. 
Single-photon emission computed tomography (SPECT) gives a 3-dimensional 
image of the lesion location, and combining CT with SPECT gives an even more 
detailed anatomical localization of the parathyroid tumor. Many cohort studies and 
large meta-analysis studies have confirmed dual-phase 99mTc-MIBI SPECT/CT to be 
superior to planar 99mTc-MIBI as well as 99mTc-MIBI SPECT scans (Ciappuccini et 
al. 2012, Garcia-Talavera et al. 2016, Wei et al. 2015). According to the meta-
analysis by Wei et al., the sensitivities of 99mTc-MIBI SPECT/CT, SPECT, and 
planar scans were 84, 66, and 63%, respectively, and they had a PPV of 95, 82, and 
90%, respectively. According to a recent review (Kunstman et al. 2013), 99mTc-MIBI 
SPECT/CT seems to be the preferred scintigraphy modality at the moment. 
Compared to planar imaging, dual-phase 99mTc-MIBI -SPECT/CT is more expensive 
(241% of the costs of planar imaging) (Lee et al. 2016) and exposes the patient to 
more radiation. The radiation doses of a planar 99mTc-MIBI scan and 99mTc-MIBI 
SPECT/CT are 3.33 and 7.8 mSv, respectively, while annual natural background 
radiation is 2.2 mSv (Minisola et al. 2016). Although SPECT/CT locates small 
adenomas and difficulty located adenomas better than a planar scan, its superiority 
before routine primary parathyroidectomies is not obvious regarding availability, 
operation time, and total cost (Hindie et al. 2015, Lee et al. 2016).  
Comparison of SPECT/CT to other scintigraphy modalities. SPECT and 
SPECT/CT can also be combined with thyroid-specific isotopes. Dual-isotope 
123Iodine/99mTc-MIBI SPECT/CT has been found to be more sensitive and specific 
than planar 123Iodine/99mTc-MIBI, with a sensitivity of 86 and 75%, and a high 
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specificity of 100 and 90%, respectively (Hassler et al. 2014). In a study of 360 
patients, planar 123Iodine/99mTc-MIBI had a sensitivity of 86% and an accuracy of 
81%, and 99mTc-SPECT or 99mTc-SPECT/CT did not increase these. In cases where 
studies were discordant, planar 123Iodine/99mTc-MIBI performed better (Lee et al. 
2016). A Finnish study comparing five different scintigraphy protocols in 24 patients 
concluded that any dual-tracer protocol with 123Iodine and 99mTc-MIBI is superior to 
99mTc-MIBI alone (Tunninen et al. 2013). The routine inclusion of SPECT or 
SPECT/CT before the primary surgery of PHPT added minimal clinical benefit only, 
but it did increase costs and radiation exposure to the patient (Lee et al. 2016, 
Minisola et al. 2016). All studies assess the capability of each method to find the 
correct side on which the abnormal gland resides. This point of view does not, 
however, take into account the depth assessment of the abnormal gland, which is the 
strength of SPECT and SPECT/CT (Lee et al. 2016). 
Factors contributing to scintigraphy sensitivity. Higher serum calcium, PTH 
levels and larger tumor size correlate with higher sensitivity in scintigraphy. There is 
a risk with MGD of negative imaging results (Berber et al. 2008, Ciappuccini et al. 
2012). In patients with negative scintigraphy, the parathyroid tumors were 
predominantly chief cells, whereas those with a positive scan consisted more often of 
oncocytic cells, known to have more mitochondria (Carlson 2010, Mihai et al. 2006).  
According to many studies, patients with negative imaging results have higher 
rates of operative failure. Allendorf et al. reported a cure rate of 92% for those with 
negative and 99% for those with positive imaging (Allendorf et al. 2003). A 
Scandinavian multicenter study reported a surgical failure rate of 17% in patients 
with negative ultrasound and scintigraphy. They had smaller pathological glands and 
a higher rate of MDG (22%) (Bergenfelz et al. 2011).  
2.7.3 OTHER IMAGING MODALITIES 
 
The methods described below are considered second-line imaging modalities and are 
mostly used in reoperative settings. Localization studies are particularly important 
before reoperation because of persistent or recurrent HPT, and two concordant 
imaging studies are recommended before reoperation (Hindie et al. 2009, Hindie et 
al. 2015). These are scintigraphy and ultrasound, and if the results are not 
concordant, one of the methods described below is used (Bergenfelz et al. 2009). 
Patients referred for primary surgery of PHPT who have undergone a non-
parathyroid related neck operation (usually due to thyroid carcinoma or goiter) are 
often considered as reoperations (Traub-Weidinger et al. 2014).  
2.7.3.1 Positron Emission Tomography/Computed Tomography 
Positron Emission Tomography (PET) imaging has better spatial and time-related 
resolution compared to SPECT, but the performance of PET depends on the tracer, 
which should be specifically taken up by the investigated organ (Kluijfhout et al. 
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2016a). The first tracer used in parathyroid PET imaging was 18fluoro-d-glucose 
(18F-FDG) (Neumann et al. 1993) but it was replaced by 11C-methionine, which has 
a better sensitivity. In a meta-analysis of 24 studies on 11C-methionine-PET/CT in 
PHPT patients, the sensitivity for the detection of a lesion in the correct quadrant had 
a pooled estimate of 77% (range 44–91%). However, this meta-analysis included 
only three studies with scintigraphy-negative patients, and two studies of reoperated 
patients with sensitivities of 54 and 84% (Kluijfhout et al. 2016a). In a study of 15 
patients with previous neck surgery and negative 99mTc-SPECT/CT, 11C-methionine-
PET/CT was positive in only six (40%) patients. Five of them were reoperated, and 
in all these cases the surgery confirmed the results of 11C-methionine-PET/CT to be 
true positives (Traub-Weidinger et al. 2014).  
2.7.3.2 Selective venous sampling  
This method was introduced for the first time in 1969 for the localization of 
parathyroid tumors (Reitz et al. 1969). Selective venous sampling (SVS) has been 
regarded as a gold standard for difficult cases, and is used when noninvasive 
localization imaging remains negative (Bergenfelz et al. 2009, Udelsman et al. 
2003). In SVS, blood sampling is performed from cervical veins after access through 
the femoral vein. Samples for PTH analyses are drawn from different locations in the 
superior, mid-cervical, and inferior parts of the right and left internal jugular veins, 
the right and left brachiocephalic veins, and the superior cava vein. A positive 
finding in SVS is a twofold increase in PTH in one sample, with an elevated but 
decreasing concentration in an adjacent sample in the direction of blood flow 
(Hessman et al. 2008). In the reoperative setting, the sensitivity of SVS has varied 
from 75 to 100% (Udelsman et al. 2003, Hessman et al. 2008, Jones et al. 2002, 
Ogilvie et al. 2006) with 12% false positives (Jones et al. 2002). 
2.7.3.3 Computed tomography and magnetic resonance imaging 
Computed tomography, performed as four-dimensional computed tomography (4D-
CT) in recent studies, and magnetic resonance imaging (MRI) are second-line 
modalities used especially in cases of ectopic parathyroid glands (Hindie et al. 
2015). The sensitivity and PPV of 4D-CT, 99mTc-SPECT/CT, and US in PHPT for a 
single gland disease were 96, 65, and 58%, respectively (Kukar et al. 2015). In 
MGD, 4D-CT had sensitivity varying between 14 and 32% (Kukar et al. 2015, 
Madorin et al. 2013). The benefit of 4D-CT is the shorter duration compared to 
scintigraphies. In patients with inconclusive or negative 99mTc-SPECT and US, the 
sensitivity and PPV of 4D-CT were 72 and 75%, respectively (Cheung et al. 2012). 
In a study of 223 patients, including 34 reoperation patients, a conventional, 
contrast-enhanced neck CT had a sensitivity of 60% and a specificity of 81% (Zald 
et al. 2008). This method (or MRI) is recommended to confirm thoracic glands found 
by scintigraphy (Hindie et al. 2015). 
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MRI does not expose the patient to radiation. The sensitivity has varied between 
64 and 82% at 3 Tesla (T) and 1.5 T magnets, respectively, before primary 
operation, but it can give additional information in most patients (57%) when US 
and scintigraphy remain negative (Lopez Hanninen et al. 2000, Grayev et al. 2012).  
2.8 SURGERY 
2.8.1 SURGICAL APPROACHES 
2.8.1.1 Bilateral neck exploration 
Bilateral neck exploration (BNE) has been the gold standard in parathyroidectomy, 
but improvements in preoperative imaging and the possibility of intraoperative PTH 
monitoring have increased the use of minimal invasive approaches (Bilezikian et al. 
2016, Udelsman et al. 2014). In bilateral neck exploration (BNE), all four 
parathyroid glands are examined under general anesthesia. BNE is recommended for 
patients with a suspicion of multigland disease (10–15% of PHPT cases), especially 
those with familial PHPT, with previous use of lithium, and for all with discordant or 
negative imaging. In the hands of an experienced parathyroid surgeon, the cure rate 
following PHPT is up to 98% by BNE and the complication rate is low (Udelsman et 
al. 2014).  
Surgery is the only possible cure for PHPT. The indications for surgery have 
been described above. A successful operation is followed by a rapid decline of serum 
calcium to normal level and a >50% decline in serum PTH concentration on the first 
postoperative day. In 10% of patients, calcium decreases slowly and reaches the 
upper limit of normal within two weeks following the operation. However, this does 
not predict a recurrence (Lai et al. 2016). 
2.8.1.2 Minimal invasive procedure  
Minimal invasive parathyroidectomies (MIP) have gained acceptance during the last 
two decades. A focused parathyroidectomy is possible when two preoperative 
localization studies are positive and concordant. In MIP, only the abnormal 
parathyroid gland and sometimes the ipsilateral gland are visualized. These 
operations can employ an endoscopic or lateral approach, which leads to a better 
cosmetic result. In some centers they can be performed under local or regional 
anesthesia, and in some high-volume centers, patients can be discharged the same 
day (Kunstman et al. 2013, Rajeev et al. 2013). Focused parathyroidectomy 
decreases the risk of laryngeal nerve injury, the devascularization of normal 
parathyroid glands and thus the risk for postoperative hypocalcemia. It also 
decreases the length of hospital stay and of operation, and, despite obligatory 
imaging studies, the total costs (Udelsman et al. 2014).  
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2.8.1.3 Other techniques for parathyroidectomy 
Thoracoscopic and mediastinal approaches are rarely needed to resect ectopic 
mediastinal parathyroid tumors. Efficient localization diagnosis has reduced the need 
for sternotomies, as most mediastinal ectopic glands can be resected using a cervical 
approach (Udelsman et al. 2014). In a study of PHPT patients reoperated between 
1987–1997 and 1998–2008, 35% and 14% underwent sternotomy, respectively 
(Karakas et al. 2013). In another study, sternotomy was used in 10% of reoperations 
(Hessman et al. 2008). 
2.8.1.4 Comparison of bilateral exploration and focused 
parathyroidectomy  
According to a retrospective two-center study over the last 23 years (Norlen et al. 
2015), 2000 focused and 2500 bilateral primary operations in sporadic PHPT led to 
persistent disease in 2.7% vs 1.7% of patients, and to long-term recurrence in 0.6% 
vs 0.4%, respectively. In these focused operations, the ipsilateral gland was revealed 
or the intraoperative PTH measurement (ioPTH) was used only in some patients. 
These results are concordant with other studies (Thier et al. 2016, Udelsman, Lin & 
Donovan 2011, Bergenfelz et al. 2002), and the Swedish prospective study reported 
a recurrence rate of only 1.1% after MIP at a 15-year follow-up (Thier et al. 2016). 
Norman et al. criticized MIP for a failure rate of 3–5% and 4–6% in their material at 
one-year and ten-year follow-up, and returned to do a BNE for 99.5% of the circa 
1000 parathyroidectomy patients operated on every year (Norman, Lopez & Politz 
2012). Complication rates in BNE and focused parathyroidecomies has varied 
between 3.1–7.3% and 1.5–3.6%, respectively (Norlen et al. 2015, Udelsman, Lin & 
Donovan 2011). In a prospective study of nearly 1600 primary operations with 
sporadic PHPT, MIPs were performed on patients with concordant preoperative 
localization studies. These operations were converted to BNEs despite an enlarged 
parathyroid gland being removed and appropriately decreased IoPTH. This revealed 
an additional pathological parathyroid gland in 15% of cases, but the prevalence of 
MGD and double adenomas in the study group were 16% and 16%, respectively 
(Siperstein et al. 2008). The cost of BNE with an intraoperative frozen section but 
without preoperative imaging equals the cost of MIP with preoperative sestamibi 
scintigraphy and ioPTH measurement (Bergenfelz et al. 2002). There is still no 
consensus on the best strategy for choosing the surgical technique in 
parathyroidectomy for PHPT (Udelsman et al. 2014).  
2.8.1.5 Parathyroidectomy for hereditary patients 
Parathyroidectomy in patients with some of the hereditary syndromes (MEN1, 
MEN4 and HPT-JT) is more challenging, because these patients more often have 
hyperplasia of all four glands. In a Dutch cohort of 73 MEN1 patients, the proportion 
of recurrent PHPT was 53% in parathyroidectomies of 1–2 glands, 17% in subtotal 
parathyroidectomy and 10% in those with additional autotransplantation of 
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parathyroid tissue in a forearm muscle. This study implies that some MEN1 
mutations may have a higher recurrence rate (Pieterman et al. 2012). The most 
commonly recommended technique for the primary operation is subtotal 
parathyroidectomy removing 3.5 glands (Iacobone et al. 2015). The advantage of 
autotransplantation of the 0.5 glands is the elimination of recurrent operations to the 
neck (Udelsman et al. 2014, Stalberg, Carling 2009). In MEN1 there is also a 15% 
risk of having parathyroid tissue in the thymus. In contrast, MEN2 and MEN3 
patients are less likely to develop recurrence, and MIP is recommended. Patients 
with familial HPT-JT syndrome are at risk of parathyroid carcinoma and recurrent 
PHPT, but the autotransplantation of 0.5 gland can cause the dissemination of 
possible cancer cells. In HPT-JT, an operation strategy similar to sporadic PHPT is 
recommended, combined with a lifelong serum calcium follow-up (Iacobone et al. 
2015). 
2.8.1.6 Reoperations in PHPT 
Patients referred for reoperation consist mostly of those with persistent PHPT after 
primary surgery. This occurs when the parathyroid adenoma cannot be located or 
when inadequate resection is performed in patients with multigland disease. 
Reoperation can be necessary for parathyreomatosis when residual hyperfunctioning 
parathyroid tissue is left due to tumor rupture. Patients with non-parathyroid-related 
neck operations, such as thyroidectomy, should also be managed as patients 
scheduled for reoperation of PHPT when planning preoperational imaging and 
assessing surgery complications (Udelsman 2011). The critical re-evaluation of the 
diagnosis and the need for the reoperation are also important before proceeding to 
preoperative imaging for a new operation (Udelsman 2011).  
In a study of reoperations performed between 1982 and 1995 (Jaskowiak et al. 
1996), 77% were due to an undetected single adenoma compared to 22% of a more 
recent study in a tertiary center (Karakas et al. 2013). In 144 reoperations (Hessman 
et al. 2008) reported, similarly to others (Jaskowiak et al. 1996), the vast majority of 
enlarged glands were located in normal positions in the parathyroid glands, but 
concealed by the irregularities of the thyroid or behind it (Figure 5). On average 10% 
of glands were intrathyroidal, another 10% were para- or retroesofageal, and nearly 
10% in the thoracic thymus. Since 1990, sternotomies have been used in 
reoperations in 10% of patients (Hessman et al. 2008).  
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Figure 5. Schematic drawing of the locations of enlarged parathyroid glands removed in 
reoperations (adopted from Hessman et al. 2008 (Hessman et al. 2008))  
Patients who have a planned reoperation are at high risk of postoperative 
hypocalcemia (up to 20%) and recurrent laryngeal nerve palsy (up to 15%) (Karakas 
et al. 2013). After primary surgery, scarring is intensive and leads to difficulties in 
distinguishing the laryngeal nerve, as well as abnormal and normal parathyroid 
glands. The type of surgery in reoperations between 1998 and 2008 was more often a 
focused parathyroidectomy than between 1987 and 1997 (23% vs 57%, 
respectively). Although the proportion of sternotomies has decreased, the cure rate of 
reoperations is similar to primary operations. When comparing the earlier and the 
later decades, the rate of laryngeal nerve palsies did not change (9% vs 9%), while 
the rate of hypocalcemia decreased (9% vs 6%) (Karakas et al. 2013).  
2.8.2 INTRAOPERATIVE METHODS 
 
Intraoperative PTH measurement (ioPTH) helps the surgeon to evaluate whether all 
the abnormal parathyroid glands have been removed or not. PTH has a mean 
circulating half-life of 3.5–4 minutes in patients with normal renal function and 
therefore the change in PTH concentration can be noticed intraoperatively. Serum 
PTH is measured before initiation of the operation. The criteria for sufficient PTH 
decline at 10 minutes after the resection is, first, a fall of ≥50% in PTH concentration 
during the operation and, secondly, a decline to the normal range of PTH (Yen et al. 
2008). Patient characteristics do not affect the half-life of PTH (Leiker et al. 2013). 
The European Society of Endocrine Surgeons (ESES) allows unilateral primary 
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operations despite disconcordant imaging studies if ioPTH is used and requires 
ioPTH measurement for all reoperations (Bergenfelz et al. 2009). Karakas et al. 
showed an increased in the cure rate of reoperations (from 91% to 98% in a decade) 
after the introduction of SPECT/CT and ioPTH (Karakas et al. 2013). Some studies 
(Siperstein et al. 2008) have shown that a sufficient fall in the intraoperative PTH 
level does not exclude the possibility of pathological glands remaining in situ. 
However, the latest guidelines (Udelsman et al. 2014) require measuring IoPTH 
during mini-invasive procedures as a confirmation of successful operation.  
In radio-guided parathyroidectomy, the identification of the hyperplastic 
parathyroid gland is performed by assessing the uptake of 99mTc-sestamibi given 
intravenously one hour prior to the operation. The gamma probe is handheld and is 
able to search for the pathological gland both through the skin and from the skin 
incision. The radioactivity of the adenoma must be over 20% of that of the 
background (You, Zapas 2007). Thyroid nodules can be false positives. The use of a 
gamma probe led to a cure rate of 96% in the reoperations (Pitt et al. 2009) and it can 
be used in a reoperative setting (Bergenfelz et al. 2009, Udelsman et al. 2014). 
Intraoperative monitoring of the recurrent laryngeal nerve requires an endotracheal 
tube and can be performed on patients under general anesthesia. In 75 
parathyroidectomies including 10 reoperations, the incidences of transient and 
permanent laryngeal nerve palsy were 3.8% and 1.3%, respectively. In this material, 
the nerve monitoring had a PPV of 97.4% and a negative predictive value (NPV) of 
50.0% (Eid et al. 2013). The recent international workshop on PHPT does not 
recommend this monitoring as a routine method in all parathyroidectomies 
(Udelsman et al. 2014). A frozen section is recommended when the surgeon is in 
doubt as to whether a nodule is parathyroid tissue (Bergenfelz et al. 2009). 
2.8.3 SURGICAL COMPLICATIONS 
 
Mortality in parathyroid surgery is near to 0%, but can be as high as 10% in elderly 
patients with other comorbidities (Morris et al. 2010).  
Postoperative hypocalcemia results from local trauma or devascularization of the 
parathyroid glands during operation of the thyroid bed. In addition, a slow PTH-
secreting response of the remaining glands due to long-term suppression of the 
removed hyperfunctioning gland exposes the patient to hypocalcemia. Within 12 to 
48 hours after surgery, hypocalcemia becomes symptomatic, including perioral 
hyperesthesia and tingling in the extremities, as well as Chvostek and Trousseau 
signs. Hypocalcemia is mostly mild and temporary, but can be severe and prolonged 
(Witteveen et al. 2013). It is related to postoperative, often temporarily suppressed 
PTH secretion after the removal of a parathyroid adenoma or to hungry bone 
syndrome (HBS), related to high bone turnover with suppressed PTH concentrations. 
Risk factors for hypocalcemia are bilateral exploration, female sex, vitamin D 
deficiency, pregnancy, lactation, autoimmune thyroid disease, and prior gastric 
bypass surgery (Stack et al. 2015). The incidence of symptomatic hypocalcemia is 
Review of the literature 
48 
lower after MIP compared to BNE, in which the risk of all parathyroids to be 
disrupted during their visualization is higher (Bergenfelz et al. 2002).  
HBS is seen in 25–90% of those with radiological findings of PHPT but only in 
5% without the skeletal involvement of PHPT. It is possible that preoperative 
bisphosphonate treatment decreases the incidence of HBS. The postoperative 
biochemical findings are hypocalcemia, hypophosphatemia, and low PTH 
concentration together with increased serum alkaline phosphatase. Serum 
magnesium can be decreased. Most studies report that PTH, serum calcium and 
alkaline phosphatase concentrations are markedly higher preoperatively in those with 
subsequent HBS than in those without HBS. Depletion of vitamin D and older age 
seem to be risk factors for HBS (Witteveen et al. 2013).  
Postoperative calcium supplementation (at a minimum 1000 mg of calcium 
carbonate daily) is used to minimize the risk of hypocalcemia (Udelsman et al. 
2014). Hypocalcemia also often needs cholecalciferole, which enhances the 
intestinal absorption of calcium and liberates calcium from bones. Hypomagnesemia 
must also be treated as it causes PTH resistance. Acute postoperative hypocalcemia 
can require intravenous calcium infusions (Stack et al. 2015). A recent pilot study of 
16 patients reports that short treatment with teriparatide is a safe and efficient option 
in treating difficult postoperative hypocalcemia (Shah et al. 2015). 
2.9 NATURAL HISTORY, SURVEILLANCE AND 
MEDICAL THERAPY 
In a 15-year follow-up study of 57 PHPT patients without parathyroidectomy, 37% 
showed disease progression fulfilling one or more criteria for parathyroidectomy. 
The calcium concentration of the 59 successfully operated PHPT patients stayed 
stable during follow-up, but their bone mineral density in the lumbar spine and 
femoral neck increased at 5 and 10 years from 6 to 12%, and from 7 to 10%, 
respectively (Rubin et al. 2008b). Other studies have reported a disease progression 
in 20% and 15% of unoperated PHPT patients at 7- and 5-year follow-ups, 
respectively (Jung et al. 2016, Yu et al. 2011). 
Unoperated patients or those not fulfilling the surgical criteria need an annual 
follow-up with serum calcium and estimated GFR measurements (Bilezikian et al. 
2014). The frequency of DXA follow-up is evaluated on an individual basis. If the 
patient has possible symptoms of renal stones, renal imaging (X-ray, ultrasound) and 
a 24-hour urine calcium and biochemical stone profile is recommended (Bilezikian 
et al. 2014).  
All patients followed without surgery should be repleted cautiously with vitamin 
D to increase the serum 25(OH)D3 level between 50 and 75 nmol/l (Bilezikian et al. 
2016, Marcocci et al. 2014). The starting dose recommendation is 600–1000 IU of 
cholecalciferol daily. In an intervention study by Rolighed et al., even a daily dose 
(2800 IU) was safe to use. This supplementation decreases PTH levels and bone 
resorption without effects on serum or urinary calcium levels (Rolighed et al. 
2014b). Calcium intake should follow the guidelines for healthy individuals; calcium 
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intake must not be limited in PHPT (Bilezikian et al. 2014). Adequate fluid intake 
and avoidance of dehydration is recommended for all PHPT patients (Bilezikian et 
al. 2016). 
Some patients refuse or are unable to undergo surgery because of comorbidities. 
For some patients even the reoperation remains unsuccessful. Of the 
pharmacological options to treat PHPT, bisphosphonates improve BMD without 
having an effect on serum calcium, and cinacalcet reduces serum and urinary 
calcium but it does not affect BMD. Alendronate is the bisphosphonate that has been 
most studied in the medical management of PHPT. Over the course of a two-year 
alendronate treatment program, BMD increases 7% in the lumbar spine with no 
changes in serum calcium, while bone turnover markers decrease by 66% at three 
months (Khan et al. 2004).  
Cinacalcet, a calcimimetic, improves the sensitivity of the CaSR for calcium and 
thus decreases serum PTH concentrations. Two prospective and randomized studies 
(Peacock et al. 2009, Saponaro et al. 2013) have consistent findings: During 
cinacalcet therapy (30 to 180 mg), serum calcium normalized in 80–90% of patients, 
and serum PTH decreased by 7% with no changes in BMD. Artralgia, myalgia and 
nausea are the most common side effects. In a study of 73 patients with mild or 
moderate PHPT and a mean serum calcium of 2.67 mmol/l, 73% achieved 
normocalcemia but three patients got hypocalcemia with the lowest dosage of 
cinacalcet. In 17 PHPT patients with a mean serum calcium of 3.2 mmol/l, the 140-
week cinacalcet treatment (mean dosage 70 mg twice a day) improved their health-
related quality of life (Marcocci et al. 2009). A quarter of patients interrupted the 
treatment due to side effects. Although there was no control group in the study, it 
suggests that cinacalcet treatment might improve the well-being and functional status 
of PHPT patients. The European Medicine Agency (EMA) has approved the use of 
cinacalcet in specific indications in patients with PHPT. This means patients in 
whom parathyroidectomy is indicated, but surgery is not appropriate or 
contraindicated. The Fourth International Workshop, held in 2014, accepted this 
recommendation (Marcocci et al. 2014). 
Denosumab has been used for the treatment of hypercalcemia in occasional, 
inoperable parathyroid carcinoma patients, but no case control studies or larger 
reports from patients with PHPT are yet available.  
2.10 CLINICAL PRESENTATION AND MANAGEMENT OF 
PARATHYROID CARCINOMA 
2.10.1 EPIDEMIOLOGY AND MOLECULAR PATHOGENESIS 
 
Parathyroid carcinoma (PC) causes 1–3% of PHPT. The incidence of this disease is 
0.4 to 0.6 per million and it seems to be increasing, according to two studies (Brown 
et al. 2011, Lee et al. 2007) that report an increase of 60% since the 1980s in the 
United States and a fivefold increase in recent decades in Australia. 
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PC is most commonly a sporadic disease. It can occur in patients with CDC73 
mutation as part of HPT-JT syndrome, but very rarely in MEN1 families. Neck 
radiation is not considered a marked risk factor for PC (Cetani, Pardi & Marcocci 
2016), but, according to a Swedish population-based study, patients with previous 
thyroid cancer or parathyroid adenoma are at increased risk for PC (Fallah et al. 
2011). The tumor suppressor gene CDC73 (described in section 3.1.1) has an 
important role in the molecular pathogenesis of PC. Germline mutation of CDC73 is 
found in up to one-third of PCs (Cetani, Pardi & Marcocci 2016), and somatic 
inactivating CDC73 mutations are present in 15–70% of patients with sporadic 
parathyroid carcinoma (Cetani et al. 2007, Haven et al. 2007, Shattuck et al. 2003). 
Interestingly, no CDC73 mutations were found in 70 sporadic parathyroid adenomas 
(Shattuck et al. 2003, Krebs, Shattuck & Arnold 2005). In contrast, an allelic loss at 
11q chromosome, a common alteration in benign parathyroid adenomas, is not found 
in PCs (Costa-Guda, Arnold 2014). These findings indicate that PC increases de 
novo and parathyroid adenoma is not a pre-existing lesion for PC. As described 
earlier (section 4.5), parafibromin, the product of the CDC73 gene, is used in 
pathological assessment as a tool in the differential diagnosis between parathyroid 
adenoma and carcinoma. 
In addition, other gene mutations in retinoblastoma, tumor protein p53 and 
PRAD1, for instance, have been linked to PC (Cetani, Pardi & Marcocci 2016). A 
recent study on whole exome sequencing in PC reports a new mutation, prune 
homolog 2 [Drosophila] (PRUNE2), in 18% of PCs (Yu et al. 2015). 
2.10.2 CLINICAL PRESENTATION 
 
The signs and symptoms of PC result from excessive PTH secretion and 
hypercalcemia rather than from tumor mass. The suspicion of PC should be raised 
when serum Ca levels exceed 3.0 mmol/l, tumor size is over 3 cm, or the patient has 
a family history of PHPT (Schulte et al. 2012).  
Compared to benign PHPT, most, but not all, PC patients have more severe 
hypercalcemia and more often renal (nephrocalcinosis, renal stones, impaired renal 
function) or skeletal manifestations (osteitis fibrosa cystica, salt and pepper skull, 
osteoporosis or fragility fractures) of this disease, especially a combination of these 
(Talat, Schulte 2010, Wei, Harari 2012). Of note, there is no gender preference in 
PC, whereas there is a female predominance in benign PHPT (3 : 1). PC patients are 
younger than those with benign PHPT. Rare, non-functioning PCs with 
normocalcemia have been described. A palpable cervical mass can be a sign of PC. 
Laboratory tests cannot differentiate between malign and benign PHPT (Harari et al. 
2011, Villar-del-Moral et al. 2014, Marcocci et al. 2008). Two small studies of eight 
and 10 PC patients suggest that urinary human chorionic gonadotropin (U-hCG) can 
be elevated in PC but remain normal in adenomas (Gupta, Mittal & Sathian 2013, 
Rubin et al. 2008a). 
Ultrasound, scintigraphy and MRI are the most commonly used preoperative 
imaging modalities when PC is suspected. The use of 18F-fluorodeoxyglucose 
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(FDG)-PET/CT was reported in a small series and was shown to be helpful when 
conventional imaging modalities were negative, but it can have false-positive 
findings in areas of inflammation (Evangelista et al. 2011).  
2.10.3 SURGICAL MANAGEMENT 
 
Surgery is the only possible cure for PC. When PC is suspected, an en bloc resection, 
including the removal of the ipsilateral thyroid gland and/or adjacent structures and 
lymph nodes, is performed (Cetani, Pardi & Marcocci 2016, Schulte et al. 2012, 
Schulte et al. 2010). This larger resection with good margins enables better 
pathological evaluation of invasion that is crucial in differential diagnosis. All 
patients with suspected PC should be referred to an experienced surgeon: This has 
been noted to affect the survival (Cetani, Pardi & Marcocci 2016, Harari et al. 2011). 
2.10.4 ADJUVANT TREATMENTS AND MEDICAL TREATMENT OF 
HYPERCALCEMIA 
 
There are no reports suggesting that chemotherapy would be beneficial in PC 
(Cetani, Pardi & Marcocci 2016, Wynne et al. 1992). Cohort studies suggest 
(Munson et al. 2003, Busaidy et al. 2004) that external-beam radiotherapy might be 
used in high-risk patients, which include those with positive surgical margins, 
intraoperative tumor rupture, and vascular invasion. There are no randomized studies 
that are possible to perform related to this rare disease. The recent reviews support 
the assessment of radiotherapy on an individual basis (Cetani, Pardi & Marcocci 
2016, Wei, Harari 2012, Schulte, Talat 2012). Doses of 40-70 Gray after surgical 
resection have been used.  
In 2004, Betea and Bradwell et al. introduced an experimental therapy for PC, i.e. 
induction of anti-PTH antibodies by immunization with PTH fragments. This 
palliative therapy led to tumor shrinkage or stopped the tumor growth. This therapy 
needs further studying (Betea et al. 2004). 
If parathyroid carcinoma is inoperable or there are metastases and hypercalcemia 
proceeds, medical therapy is warranted. Debulking of metastasis, if possible, can 
reduce serum calcium levels. Rehydration and furosemide can be used in mild 
hypercalcemia. Zoledronic acid and cinacalcet are used in more severe 
hypercalcemia (Cetani, Pardi & Marcocci 2016, Silverberg et al. 2007). Cinacalcet is 
used to reduce serum calcium in PC. Denosumab, a monoclonal antibody against 
RANK ligand, has been shown to lower serum calcium levels in PC (Vellanki et al. 
2014, Nadarasa et al. 2014). However, these situations have required higher dosages 
than in conventional use, and the safety of this treatment is uncertain (Tong, Hussein 
2016).  
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2.10.5 PROGNOSIS AND SURVIVAL 
 
The recurrence rate in PC is between 40 and 60% according to most reports (Harari 
et al. 2011, Talat, Schulte 2010, Sadler et al. 2014), but only 23% according to a 
recent Spanish cohort (Villar-del-Moral et al. 2014). Most recurrences occur within 
2–3 years, and are local (Cetani, Pardi & Marcocci 2016). Lymph node metastasis 
can occur. The lungs and bone are the most common sites for distant metastasis. PC 
patients experience recurrences and 60% of them suffer complications due to 
reoperations to the neck (Harari et al. 2011). 
Reported data suggests that there is an overall survival rate at 10 years in the 
range of 49–77% (Harari et al. 2011, Lee et al. 2007, Busaidy et al. 2004, Hundahl et 
al. 1999, Sandelin et al. 1992), but 19% at a 55-month follow-up in the Spanish 
cohort (Villar-del-Moral et al. 2014). 
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3 AIMS OF THE STUDY 
The specific aims of this present study were: 
 
1) To assess the accuracies and surgical benefits of 123I/ 99mTc-MIBI dual-phase 
scintigraphy compared to dual-phase 99mTc-MIBI scintigraphy before primary 
operation of PHPT. 
2) To compare the planar dual-phase 123I/ 99mTc-MIBI scintigraphy, 99mTc-MIBI-
SPECT/CT, selective venous sampling (SVS) and 11C-methionine PET/CT in 
localizing parathyroid tumors before reoperation of PHPT. 
3) To compare health-related quality of life in PHPT patients to that of an age- and 
gender-adjusted sample from the general population, and to evaluate the possible 
effect of surgery on HRQoL in PHPT. 
4) To investigate whether the incidence of parathyroid carcinoma in Finland changed 
between1955 and 2013. 
5) To collect data on all the parathyroid carcinoma patients diagnosed in Finland 
between 2000 and 2011, and to improve the understanding of the disease by 
comparing clinical and histological characteristics of parathyroid carcinoma, atypical 
parathyroid adenoma, and parathyroid adenoma. 
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4 PATIENTS AND METHODS 
4.1 PATIENTS AND DATA COLLECTION 
 










primary operation  
269 PHPT patients referred for 
primary operation  




Localization before a 
reoperation  
21 patients with PHPT after first 
one or two parathyroid 
operations  





of life before and after 
surgery  
124 PHPT patients referred for 
operation 





histological aspects of 
parathyroid carcinoma 





32 PHPT patients with PC 
finding in the operation. 
28 PHPT patients with APA 
finding in the operation. 
72 gender- and age-adjusted 
PHPT patients with parathyroid 
adenoma finding in the 
operation. 
2000-2011 Table 1 
 
 
Table 1. Summary of the thesis study patients. 
 
Study I. Patient data was retrospectively collected from 543 consecutive patients 
referred for parathyroid scintigraphy between November 2006 and November 2009 
at Helsinki University Hospital Medical Imaging Center, in the Department of 
Clinical Physiology and Nuclear Medicine. The final study cohort consisted of 269 
PHPT patients who underwent the primary operation for PHPT in the hospitals of the 
Hospital District of Helsinki and Uusimaa (HUS). Clinical, laboratory and imaging 
data was collected retrospectively from medical records. 
on follow-up, possible reoperations, and other treatments was collected. The 
patients Study II included 21 patients with persistent PHPT referred to Helsinki 
University Hospital for reoperation. The patients were prospectively investigated 
with 123I/ 99mTc-MIBI scintigraphy, 99mTc SPECT/CT (n = 19), 11C-methionine-
PET/CT, and SVS (n = 18) before surgery, and were reoperated on between 
November 2009 and February 2012. None of the patients had been diagnosed for a 
familial form of PHPT. Seven patients had no pathological glands removed in the 
previous operation(s). Fourteen of the 21 study patients had a persistent PHPT and at 
least one pathological parathyroid gland previously removed, so they had a 
multiglandular PHPT. These previous operation(s) revealed 1–2 hyperplastic 
gland(s) in eight patients, an adenoma in five patients and an atypical adenoma in 
one patient.  
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Study III comprised 124 PHPT patients operated on for the disease at the 
Department of Surgery at Helsinki University Hospital between October 2010 and 
May 2013. All patients who completed the 15D questionnaire preoperatively were 
included. Demographic, biochemical, and clinical data as well as surgery results 
were collected from the patient register of the hospital. The HRQoL of the study 
patients, as assessed by the 15D instrument, were compared to that of an age- and 
gender-standardized sample of the Finnish general population from the Finnish 
Health 2011 survey (n = 4924) (201). Fifty-one of the 124 patients (41.4%) suffered 
from possible PHPT-related symptoms such as fatigue, depression, loss of memory, 
abdominal pain or nausea, muscle weakness, or joint pain. The surgical criteria for 
PHPT according to the Third International Workshop on the Management of 
Asymptomatic PHPT in 2008 (Udelsman et al. 2009b) were met by 80.6% of 
patients: 48.3% had osteoporosis, 13.7% had impaired kidney function, 29.0% had 
serum ionized calcium over 1.50 mmol/l, 9.7% were under 50 years of age, and 7.3% 
had kidney stones.  
Study IV included 39 patients diagnosed with parathyroid carcinoma in Finland 
between 2000 and 2011. The PC patients were identified from the Finnish Cancer 
Registry, from the database of the Department of Pathology (Huslab and University 
of Helsinki, Finland), from the hospital databases of the Finnish university hospitals, 
and from eight Finnish central hospitals using the International Classification of 
Diseases 10 (ICD-10) code (C75.0). The PCs confirmed to have unequivocal 
invasion or metastasis according to the 2004 WHO classification (Grimelius et al. 
2004). In three patients, PC could not be confirmed and were excluded from the 
study. Four other patients’ PCs were reclassified as APAs. The final PC group 
consisted of 32 patients. All the 28 APA patients retrieved from the Helsinki 
pathology database and that were diagnosed between 2000 and 2011 were included. 
The 72 parathyroid adenoma patients (A) also retrieved from the Helsinki pathology 
database were matched for age and gender with regard to the PC group.  
Clinical, biochemical, and surgical data as well as data were monitored until 
death or until the end of follow-up (August 30th, 2015). The survival data and cause 
of death of the study patients were obtained from Statistics Finland. The nationwide 
number of PC cases from 1955 to 2013 was retrieved from the Finnish Cancer 
Registry.  
4.2 LABORATORY MEASUREMENTS  
Data on available laboratory measurements from medical records was collected from 
the time of diagnosis until the end of follow-up. All laboratory tests were performed 
at Huslab (and in Study IV at the central laboratories of each hospital taking part in 
the study) using in-house methods and standard accredited assays.  
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4.3 IMAGING TECHNIQUES AND EVALUATION OF THE 
LOCALIZATION STUDIES 
All imaging studies except the PET/CT of Study II and those of Study IV evaluated 
outside the Hospital District of Helsinki and Uusimaa were performed at Helsinki 
University Hospital Medical Imaging Center, in the Department of Clinical 
Physiology and Nuclear Medicine. The imaging studies of patients treated in other 
hospital districts were performed in those hospitals. All PET/CTs were performed at 
Turku PET center. 
4.3.1 IMAGING TECHNIQUES  
 
The planar and SPECT/CT scintigraphies were performed according to the 2009 
guidelines of the European Association of Nuclear Medicine (Studies I, II, IV) 
(Hindie et al. 2009). A 123I-capsule of 13-15 MBq was administered three hours 
before imaging. Immediately after the planar 123I-imaging, 790-940 MBq of 99mTc-
MIBI was injected intravenously and an early planar acquisition started after five 
minutes. An all-purpose collimator was used for planar imaging. 123I-images were 
subtracted from 99mTc-MIBI images. Dual-phase 99mTc-MIBI planar scintigraphy 
(Studies I and IV) comprises early and late planar 99mTc-MIBI images. The 99mTc-
MIBI images from Study I were obtained from 123I -99mTcMIBI images.  
In the 11C-methionine PET/CT (Study II), patients fasted for six hours before the 
study. Twenty minutes after intravenous injection of 11C-methionine (440 MBq), 
static PET/CT imaging in 3-dimensional mode covering the head and neck and 
mediastinum was started. A low-dose CT protocol was performed for attenuation 
correction.  
SVS (Study II) was performed at Helsinki University Central Hospital by an 
experienced intervention radiologist. Nineteen samples were taken from each patient 
through the femoral vein in different veins (Jones et al. 2002), and analyzed for PTH.  
Ultrasounds (Study IV) were performed by radiologists as a routine hospital 
procedure. 
4.3.2 THE IMAGING RESULT EVALUATION 
 
Studies I and II: The side of the abnormal gland was reported. The scintigraphy was 
considered accurate if the lesion(s) detected by the localization technique was 
removed from the same side in the operation, patients reached normocalcemia, thus 
no pathological glands remained in the patient, and the removed gland(s) was/were 
pathological (hyperplastic, adenoma, or carcinoma).  
To confirm the reproducibility of results in Study I, two experienced nuclear 
medicine physicians re-evaluated the data blindly. The original and re-evaluation 
reports differed in 4.8% of cases. In Study II, all scintigraphy studies were reviewed 
by five investigators. 
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Study II: SVS: A twofold increase in PTH in one sample, with an elevated but 
decreasing concentration in a second adjacent samples in the direction of venous 
blood flow, was considered to be a positive result. The positive SVS findings were 
categorized into six groups, corresponding to different locations.  
4.4 SURGERY 
Studies I–III: All operations were performed by an experienced parathyroid surgeon 
at Helsinki University Hospital except one patient in Study II (no. 17) who was 
operated on at Satakunta Central Hospital. 
Study I: The type of surgery depended on the preoperative localization review, 
but any condition indicating of the possibility of hyperplasia favored bilateral neck 
exploration (BNE). In unilateral neck exploration (UNE), only the side of the 
expected pathological gland was dissected. In focused parathyroidectomy or minimal 
invasive parathyroidetomy (MIP), only the suspected gland was dissected. 
Study II: Based on the preoperative imaging results, one patient underwent a 
sternotomy in addition to neck surgery, and a thoracic surgeon participated in this 
operation.  
Study IV: The types of operation were classified into two groups: Local 
resections (removal of the tumor following the peritumoral capsule), or en 
bloc/radical resections (with at least a parathyroidectomy with the removal of the 
ipsilateral thyroid lobe, adjacent structures or lymph nodes). 
The criteria for surgery in the studies were those of the Third International 
Workshop in use between 2008 and 2014 (see section 6.3). Normal serum ionized 
calcium and a 50% decrease in serum PTH concentrations on the first postoperative 
day were considered as a remission criteria for PHPT. In severe hypercalcemia, a 
slower decrease to normocalcemia within one month was accepted. Recurrent PHPT 
cases were confirmed as having hypercalcemia and an elevated serum PTH level. In 
Study IV, recurrent PCs were confirmed as also having a pathological parathyroid 
gland at reoperation.  
4.5 CDC73 GENE MUTATION ANALYSIS, 
HISTOLOGICAL, AND IMMUNOHISTOCHEMICAL 
STUDIES 
Study I: All the removed glands were analyzed by pathologists, and classified as 
normal, hyperplastic, adenoma, carcinoma, or hyperplasia/adenoma tissue (if a 
differential diagnosis was not possible). The diagnosis of a multiglandular disease 
(MGD) was set when two or more pathological parathyroid glands were removed, or 
when removal of one hyperplastic or adenoma gland did not lead to normocalcemia 
and the disease continued. 
Study II: All tissue and glands removed both in the previous neck operations and 
in the reoperation were re-evaluated by an experienced pathologist. 
PATIENTS AND METHODS 
58 
Study IV: Formalin-fixed and paraffin-embedded tissue samples of the primary 
operations were retrieved for all patients and re-examined. Immunohistochemical 
studies were performed using the Tissue Micro Array (TMA) technique. For 
construction of the TMA blocks, between three and six cores were sampled from 
representative areas of each tumor specimen and inserted into a recipient paraffin 
block. TMA blocks were cut into 4-µm sections and prepared for further staining. 
MIB-1 and parafibromin antibodies as well as PTH were incubated in appropriate 
solution concentrations with a distinct incubation time for each marker.  
The Ki67 proliferation index by MIB-1 staining was assessed by the 
Immunoratio program as described by Tuominen et al. (Tuominen et al. 2010). The 
parafibromin staining was considered positive (2) if >95% of the nuclei of the 
neoplastic cells in the TMA spot were positive, and negative (0) if >99% of all these 
nuclei were negative (Kim et al. 2012). Counts between these cut-offs were 
considered as weak positives (1). PTH stains were considered negative or positive. 
The CDC73 gene mutation analysis was performed for 18 PC and 16 APA, 27 of 
them were collected and analysis during the study, and others were analyzed at 
diagnosis. Genomic DNA was extracted from blood samples and next generation 
targeted sequencing was performed for the 17 exons of CDC73 gene. Multiplex 
ligation-dependent probe amplification (MPLA) analysis was performed to detect 
deletions and duplications of the CDC73 gene. 
 
4.6 MEASURING HEALTH-RELATED QUALITY OF LIFE 
Health-related quality of life was assessed by the 15D. The 15D is a generic, 
standardized, well-validated, and self-administered questionnaire to measure 
HRQoL. It can be used as a profile or a single score to describe HRQoL (Sintonen 
2001). Each dimension (mobility, vision, hearing, breathing, sleeping, eating, 
speech, excretion, usual activities, mental function, discomfort and symptoms, 
depression, distress, vitality, and sexual activity) has five levels. The results of 
HRQoL are also reported as a distribution of the clinically important changes of 15D 
on the Global Assessment Scale to improve the understanding of the results (Alanne 
et al. 2015). 
In Study III, a 15D questionnaire (Appendices 1–2) and an explanatory letter 
were mailed to the patients along with the surgical invitation letter. An additional 
questionnaire assessing education level (Appendix 3) was sent along with the first 
15D. It is not possible to count the total number of questionnaires sent from three 
surgical units over three years. Those one hundred and twenty-four patients who 
returned this preoperative questionnaire received two 15D questionnaires six and 12 




The statistical analyses were carried out using a SAS software (S+ version 8.1 for 
Study II, version 9.2 for study I + IV; SAS Institute Inc.). A P-value less than 0.05 
was considered statistically significant.  
Study I: McNemar and Fisher’s test exact tests were used to compare operative 
and imaging findings and the accuracy between 123I /99mTc-MIBI and 99mTc-MIBI 
scintigraphies. The duration of the operative procedures was log-transformed before 
comparison according to the type of surgery with one-way analysis of variance. 
Tukey’s method was used for pairwise comparisons between the different types of 
surgery. All tests were used as two-sided tests. 
Study II: Differences in laboratory measurements were assessed with the 
Wilcoxon signed-rank test and Student’s t-test. McNemar’s test was used to compare 
SVS, SPECT/CT, and PET/CT to 99mTc /123I planar scintigraphy, which was used the 
reference method. Cohen’s 𝜅-coefficient was calculated to quantify agreement of 
accuracies between the techniques. 
In Study III, Student’s t-test was used to test the statistical significance of the 
differences in the continuous variables. The association between the baseline 15D 
score and some independent variables was evaluated with linear regression. Binary 
logistic regression was used to evaluate the association of those variables and 
improvement of 15D scores. 
Study IV: Statistical significance between the three subgroups was evaluated 
with Fisher’s exact test for categorical variables and with the Kruskal-Wallis test for 
continuous variables. Correlation between immunohistochemical results of the 
original samples and of TMA was assessed with Pearson’s correlation coefficient, 
and survival analysis with the Kaplan-Meier method, respectively. The number of 
new PC cases were compared to the respective average Finnish adult population over 
the specific time periods (1955–2013) with a chi square-test. Incidence rates are 
reported as average annual incidences per 10,000,000 population. 
4.8 ETHICS 
All studies were conducted according to the guidelines of the Declaration of 
Helsinki and their protocols were approved by the Ethical Committee of the Helsinki 
University Central Hospital (Turku University Central Hospital for Study II). In 
Study III, all patients gave their signed informed consent to participate in the study. 
The Study IV protocol was also approved by the ethics committees of four other 
university hospitals in Finland, by the National Supervisory Authority for Welfare 
and Health in Finland (Valvira), and by the National Institute for Health and Welfare 




5.1 COMPARISON OF DUAL-PHASE 123I/ 99MTC-MIBI AND 
99MTC-MIBI SCINTIGRAPHIES BEFORE PRIMARY 
OPERATION FOR PHPT (STUDY I) 
5.1.1 CHARACTERISTICS AND IMAGING FINDINGS OF THE STUDY 
COHORT.  
All the 269 study patients had PHPT and were referred for the first 
parathyroidectomy. Patients with familial forms of PHPT were excluded. Patients 
underwent a primary operation for PHPT had a mean age of 61 (16–91) years and 
74% of them were female (Table 2). 123I/ 99mTc-MIBI scintigraphy revealed one (n= 
193) or two (n=13) findings in 206 (76.6%) patients. 99mTc-MIBI scintigraphy had 
one finding in 102, and two findings in nine patients; a total of 111 patients (41.3%; 
P < 0.001). Surgery was successful in 245 (92.5%) of the 269 study patients. Sixteen 
of the 19 failures (84.2%) were related to the multiglandular disease (MGD).   
 
 
 All study patients 
(n=269) 
Single adenomas  
detected in 123I/ 
99mTc-MIBI scan 
(n=159) 
Single adenomas not 






1.49 (1.30–2.42) 1.46 (1.3–2.24) 1.43 (1.3–1.74) 0.014* 
Serum PTH (µg/l) 159 (53–3765) 168 (71–1887) 133 (82–388) 0.0055* 
Serum 25-OHD 
(nmol/l) 
42.5 (13–99) 44 (14–98) 48 (22–67) 0.68 
Serum creatinine 
(mmol/l) 





9.02 (0.49–29.38) 8.00 (0.69–18.56) 0.37 
Weight of adenoma 
(g) 
0.65 (0.037–22) 0.78 (0.08–8.49) 0.35 (0.13–1.30) <0.001* 
All data presented as median and range. *P-value < 0.05 was considered significant (for a 
comparison of single adenomas detected and not detected by 123I/ 99mTc-MIBI scan).  
Table 2: Characteristics of the study patients and of those with single adenoma 





5.1.2 COMPARISON OF 123I/99MTC-MIBI AND 99MTC-MIBI 
SCINTIGRAPHIES  
123I/99mTc-MIBI and 99mTc-MIBI scintigraphies were positive in 77% and 41% of 
patients, respectively (P < 0.001) (Table 3). Table 2 show the accuracies of the two 
scintigraphy techniques in single gland and multiglandular disease (MGD).  
The 123I/99mTc-MIBI scan demonstrated one finding in 193 patients. In 164 (85%) of 
these, the scan result was accurate and those patients were cured. In 17 patients the 
operation was extended to a BNE and the pathological gland or an additional 
pathological gland was found on the contralateral side. Twelve patients were not 
cured; ten of these had MGD.  
Thirteen (4.8%) of 269 patients had a bilateral finding on 123I/99mTc-MIBI 
scintigraphy, and only 77% of these were cured. The accuracy was 46%, but rose to 
69% when the reoperation findings were also evaluated. 123I/99mTc-MIBI 
scintigraphy demonstrated no uptake in 63 (23%) patients, and 54 (86%) of them 
were proved to have a single gland disease, seven had a MGD and two had no 
pathological glands identified. 
5.1.3 COMPARISON OF SCINTIGRAPHIC AND HISTOPATHOLOGICAL 
FINDINGS 
Histopathology confirmed a single adenoma in 218 (81%) of the study patients. 
123I/99mTc-MIBI and 99mTc-MIBI scintigraphies were accurate in 76% and 42% of 
patients (P < 0.001). For the 47 patients with other histological diagnoses 
(hyperplasia, a combination of hyperplasia and adenoma, carcinoma) or 
multiglandular disease, 37 out of 76 (49%) pathological glands were accurately 
found in 123I/99mTc-MIBI scintigraphy. All parathyroid carcinomas were found by 
the 123I/99mTc-MIBI scan. 
 
 








99mTc-MIBI  58.7% 37.9% 3.3% 34.2%*        (28.5–
40.2) 
9.7%*    
(0.6–18.8) 
123I/99mTc MIBI 23.4% 71.7% 4.8% 60.9%*          (54.9–
66.8) 
14.6%*   
(3.8–25.5) 
* P- value < 0.001 for comparison of accuracies between 123I/99mTc-MIBI and 99mTc-MIBI 
scintigraphies. Data presented in percentages and 95% confidence intervals.    # in the whole cohort 
 
Table 3: Outcome of 123I/99mTc-MIBI and 99mTc-MIBI scintigraphies and accuracies 





5.1.4 MULTIGLANDULAR DISEASE (MGD) 
 
The rate of MGD in this cohort was 15.7%. The accuracies of 123I/99mTc-MIBI and 
99mTc-MIBI scans are shown in Table 2. The cure rate in MGD was 61.0%.  
5.1.5 DETERMINANTS OF TRUE POSITIVE 123I/99MTC-MIBI 
SCINTIGRAPHY FINDINGS 
 
Comparison of single adenomas detected and not detected on scintigraphy showed 
that patients with an accurate 123I/99mTc-MIBI scintigraphy result had higher tumor 
weight, preoperative serum ionized calcium and PTH levels than those with a 
negative scintigraphy (Table 2) (P < 0.05). 
5.1.6 EFFECT OF LOCALIZATION FINDINGS TO OPERATIVE 
TECHNIQUE AND TIME 
 
In the study cohort, bilateral neck exploration (BNE) was performed in 103 patients 
(38.2%): 88.9% of those with a negative 123I/99mTc-MIBI scintigraphy and 22.8% of 
those with a positive 123I/99mTc-MIBI scan underwent BNE (P < 0.001). A unilateral 
operation was performed in 166 patients: 54 of these were unilateral neck 
explorations (UNE) to two quadrants of the neck, and 102 were targeted to one 
quadrant (97 focused parathyroidectomies and 15 minimal invasive 
parathyroidectomies). The cure rate between patients with negative or positive scan 
did not differ (93.7% vs 92.7%, P = NS). 
The duration of the operative procedure was assessed in the 219 cured patients 
without simultaneous thyroid surgery. The median operation lengths (range) in BNE, 
in UNE to two quadrants and to one quadrant were 67.9 (33.0–181.2), 52.4 (33.0–
160.0) and 46.2 (22.0–135.0) minutes (P < 0.001 for all comparisons).  
 
5.2 COMPARISON OF PREOPERATIVE 123I/99MTC-MIBI 
PLANAR SCINTIGRAPHY, 99MTC-MIBI SPECT/CT, 
11C-METHIONINE PET/CT, AND SVS BEFORE 
REOPERATION IN PHPT 
5.2.1 PATIENT CHARACTERISTICS 
 
All the 23 study patients had a PHPT with a persistent hypercalcemia after the first 
one or two operations. The mean age of the patients was 55 years (range 31–78) and 
23.8% were men. Postoperatively, the mean (SD) serum ionized calcium and PTH 
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levels decreased significantly from preoperative levels (1.46 ± 0.09 vs. 1.25 ± 0.10 
mmol/l and 169 ± 95 vs. 48 ± 64 ng/l, respectively, P <0.001 for both). The cure rate 
for the reoperations was 86% (18/21). Nineteen pathological glands were removed 
from 17 patients, one biochemically cured patient had no abnormal glands removed. 
Two patients had the pathologic parathyroid gland located within the thyroid gland, 
and two patients in the mediastinum. 
5.2.2 COMPARISON OF 123I/99MTC-MIBI SCINTIGRAPHY, 99MTC-MIBI 













N (focuses) 14 5 17 20 
N (false 
predictive) 
0 0 1 9 
Accuracy 
(correct side of 
neck) 




48% (27–69) 14%# (3–36) 61% (39–80) 25% (9–49) 
Data presented as percentages with a 95% confidence interval. * P- value < 0.01 and # P- value < 
0.02 vs 123I/99mTc-MIBI scintigraphy  
 
Table 4. Summary of the findings and the accuracies of the four different 
localization techniques.  
 
Results of the comparison of the four localization techniques are presented in Table 
4. In one patient only, all four imaging techniques correctly localized the 
pathological parathyroid gland. In the three patients with persistent disease after 
reoperation, no pathological parathyroid tissue was removed. In all these three 
patients, 123I/99mTc-MIBI scintigraphy and SPECT/CT were negative while SVS was 
false predictive. 11C-methionine-PET/CT was false predictive in one of these three 
patients. There were four patients cured by the reoperation, in whom 11C-
methionine-PET/CT correctly identified the four pathological glands while the three 




5.3 HEALTH-RELATED QUALITY OF LIFE (HRQOL) 
BEFORE AND AFTER PARATHYROIDECTOMY IN 
PRIMARY HYPERPARATHYROIDISM 
5.3.1 PATIENT CHARACTERISTICS 
 
The study comprised 124 PHPT patients who were referred for surgery and had 
completed the 15D questionnaire preoperatively. The mean age of the patients was 
65 ± 10 years and 81.5% of them were women. The biochemical and clinical 
features of the study cohort are presented in Table 5. Parathyroidectomy resulted in 
normocalcemia in 112 of 125 (89.6%) patients. The sample of the general population 
(n=4295) was adjusted for age and gender. Of those 124 respondents to the first 15D 
questionnaire, 94.4% replied to the questionnaire at six months and 93.5% at 12 
months.  
 
 Mean ± SD (or n)  
Age (y) 65 ± 10 
N (women/men) 101/23 
Number on regular medication  3.9 ± 2.9 
Educational level 56/66/3 
Preoperative serum ionized calcium (mmol/l) 1.47 ± 0.12 
Postoperative serum ionized calcium (mmol/l) 1.25 ± 0.08 
Preoperative serum PTH (ng/l) 176.3 ± 155.6 
Postoperative serum PTH (ng/l) 35.8 ± 33.4 
Serum 25-OH D (nmol/l) 57.2 ± 17.8 
 
Table 5. Characteristics of 124 study patients before surgery 
5.3.2 HRQOL IN PHPT COMPARED TO AGE- AND GENDER-
ADJUSTED CONTROLS 
 
The mean total preoperative 15D score of PHPT patients was significantly lower 
compared to that of the controls (P < 0.001). All five dimensions measuring 
cognitive and psychiatric well-being were severely impaired compared to controls as 





5.3.3 IMPACT OF PARATHYROIDECTOMY ON HRQOL IN PHPT 
 
Figure 6 presents a significant difference both in total 15D score and in 13 of 15 
dimensions when comparing the preoperative 15D of PHPT patients with age- and 
gender-adjusted patients. Figure 6 also shows an increase in the 15D score in PHPT 
patients from a baseline at six months after surgery (P < 0.001). After surgery, 
77.4% of patients experienced at least a minimum clinically important improvement 
and 13.7% a minimum clinically important deterioration in HRQoL. The change of 
15D was significant in 10 of the 15 dimensions. There was no significant difference 
in the postoperative change of 15D between the patients meeting (80.6%) and those 
not meeting (19.4%) the Third International Workshop Criteria for surgery in PHPT 
(see section 6.3). Nearly half (42%) of the 125 patients had reported possible PHPT-
related symptoms (fatigue, depression, loss of memory, abdominal pain or nausea, 
muscle weakness, or joint pains). 
 
 
Figure 6. Health-related quality of life in patients with primary hyperparathyroidism 
before and after surgery 
5.3.4 PREDICTORS OF PREOPERATIVE HRQOL AND OF CHANGE IN 
HRQOL IN PHPT 
 
Of several possible factors evaluated, only the number of medications (β = -0.012, P 
< 0.001) and whether one experienced subjective symptoms (β = -0.040, P < 0.029) 























Population     0.904
Baseline        0.813
6 mos            0.865
12 mos          0.878
Baseline vs 6 mos p<0.001
Baseline vs 12 mos 
p<0.001
Baseline vs population 
p<0.001
Baseline vs 6 mos
# p < 0.05
## p < 0.01
### p < 0.001
Baseline vs 12 mos
* p < 0.05
** p < 0.01
*** p< 0.001
***
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significance (β = 0.001, P = 0.051) in predicting impaired HRQoL. Only higher 
educational level predicted improved HRQoL in PHPT of the different variables 
assessed, and a low preoperative 15D score was of borderline significance (P = 
0.057). 
 
5.4 INCREASING INCIDENCE OF PARATHYROID 
CARCINOMA – A NATIONWIDE STUDY INCLUDING 
CLINICAL AND HISTOLOGICAL COMPARISON TO 
ATYPICAL AND BENIGN PARATHYROID 
ADENOMAS 
5.4.1 INCIDENCE OF PARATHYROID CARCINOMA BETWEEN 1955 
AND 2013 
 
Figure 7 shows the change in incidence of PC. Between 1955 and 2000, the mean 
incidence of PC was 1.4 cases/10,000,000 persons per year (range 0.5–2.1), but this 
rose to 3.4 cases/10,000,000 persons per year (2000–2004) and up to 10.4 
cases/10,000,000 persons per year (2010–2013), P < 0.001 (Figure 7). 
 
Figure 7. Incidence of parathyroid carcinoma between 1955 and 2013 in Finland. 
5.4.2 CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF THE 
STUDY PATIENTS 
 
Of the 32 patients with PC, 18 (56%) were female and 14 (44%) male. The median 
age at diagnosis was 61 (17–83), 59 (31–84) and 62 (15–83) years for the PC, APA, 
and PA subgroups, respectively (Table 6). In the PC group, the median age of 
women and men was 68 (48–84) and 54 (17–76) years, respectively, and the median 
follow-up time (FU) was 6.7 (range 2.0–13.9) years. The characteristics of patients 
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in the PC, APA, and PA groups are presented in Table 5. Of the PC patients, 44% 
had a hypercalcemic crisis or a hospital-treated hypercalcemia. A third (35%) had a 













Ca-ion (mmol/l) 1.76  (1.61–1.97) 1.56 (1.50–1.70) 1.44 (1.38–1.51) <0.001 
PTH (ng/l)  989   (461–1518) 355 (149–959) 160  (122–251) <0.001 
Renal manifestation 
 
16    (50%) 
 
13  (48%) 16   (22%) 
 
0.010 
Bone manifestation 15    (47%) 4   (15%) 27   (38%) 0.002 
Both renal and bone 
manifestations 
9    (28%) 2    (7%) 4   (6%) 0.004 
All continuous variables are presented as medians and interquartile range (IQR). Normal ranges: 
ca-ion 1.15–1.30 mmol/l, PTH 15–65 ng/l. 
 
Table 5. Clinical and biochemical characteristics of PC, APA, and PA groups.  
5.4.3 PREOPERATIVE LOCALIZATION STUDIES AND SURGERY 
 
Planar isotope imaging with 99mTechnetium-sestamibi alone or combined with 
123Iodine did not differ in the PC compared to the APA or PA groups (P = 0.62), but 
the subgroups differed in ultrasound imaging (accurate finding in 77%, 43% and 
39% of PC (n= 26), APA (n= 23), and PA (n=64) groups, respectively, P < 0.001) 
The proportions of successful primary operation in the PC, APA, and PA subgroups 
were 91%, 93% and 91%; and the postoperative status of one APA patient remains 
unknown. En bloc or radical resection was performed on 47%, 18% and 8%, 
respectively (P < 0.001). The PC tumors were significantly larger compared to APA 
and PA tumors (2.95 (2.0–3.0) cm, 2.0 (1.4–3.0) cm, and 1.6 (1.2–2.0) cm, 
respectively, P < 0.001) 
5.4.4 HISTOLOGY 
 
Histological findings are shown in Table 7. Capsular, vascular, and perineural 
invasions were present in 72%, 72%, and 9% of the PC specimens, and were, by 
definition, absent in APA and PA tumors. In PC tumors, chief cell type and diffuse 
growth pattern dominated. Differences in mitotic activity, nuclear atypia necrosis, 

















Mitotic activity:  
Strong mitotic 
activity (>1/10 cells) 
8    (25%) 
2 
3    (9%) 
1 
1   (1%) 
0 
0.001 
 Nuclear atypia 14  (44%) 5    (18%) 8   (11%) 0.003 
Dominant cell 
type  
Chief        100% 
            ≥ 50% 
22  (69%) 
28  (88%) 
19   (68%) 
23   (82%) 
30  (41%) 





Diffuse      ≥50%     
            100%                         
24  (75%) 
20   (63%) 
17   (61%) 





Necrosis  3    (9%) 0 0    0.024 
 
Table 7. Histological findings in the different subgroups 
5.4.5 IMMUNOCHEMISTRY AND CDC73 MUTATION ANALYSIS 
 
Of PC tumors, 13% had a negative and 22% a positive parafibromin stain (Table 8). 
None of the adenoma tumors had a negative and 76% had a positive stain. Ki-67 
indices analyzed by Immunoratio (TMA) were significantly higher compared to 
APA and PA groups (P < 0.001). 
CDC73 gene mutation was analyzed in 56% and 57% of the PC and APA patients, 
respectively. The mutation was detected in one 18-year-old man with negative 
parafibromin staining in his PC sample, and in one 31-year-old man with a weak 






























# median and range, a for comparison of three subgroups, for PC vs PA, and for APA vs PA 
b for comparison of PC vs APA 
 
Table 8. Immunohistochemical results obtained from the Tissue Micro Array and 




5.4.6.1 Recurrences and mortality 
In PC, three patients had a persistent disease (Table 9). Five of the six patients with 
recurrence (at a median of 24 months from primary operation, range 4–60) 
developed distant metastasis during FU. Four of them (12.5% of all PCs) died of 
disease a median of 43.9 (range 23.4–61.3) months after diagnosis. Overall 5- and 
10-year survivals in PC did not differ from APA and PA (91% vs 84% vs 92%, and 
72% vs 73% vs 83%, respectively, P= NS for both comparisons). In APA, all deaths 
occurred in cured patients and were unrelated to PHPT. 
5.4.6.2 Treatments 
The number of operations and other treatments given are shown in in Table 8. The 
prevalence of both transient or persistent hypocalcemia and laryngeal nerve palsy 
were significantly increased in the PC group compared to APA and PA (56% vs. 
11% vs. 4% and 34% vs 11% vs 3%, respectively P < 0.001 for both). In PC 
patients, preoperatively increased creatinine did not improve after surgery. 
Preoperative and 1-year after operation, serum creatinines were 106 (76–147) and 
100 (80–145) µmol/l, respectively (P = 0.39). Of PC patients, 22% received 
radiotherapy and 13% chemotherapy. 
 







Persistent disease 3 2 0  
Recurrence 6    (21%) 1  1   
Total number of 
operations for 
PHPT (mean and 
range) 
2     (1–5) 
 
1  (1–4) 
 
1  (1–3) 
 
< 0.001 
≥ 2 neck 
operations 




5 (cervical lymph nodes, 
lungs, bone) 
0 0  
 
Table 9. Recurrences and treatments in the different subgroups 
5.4.7 FACTORS ASSOCIATED WITH CANCER DEATHS 
 
Recurrent PCs and non-recurrent PCs differed in the presentation of lymph node 
metastases (in 33% vs. 0%, P = 0.03), in parafibromin expression (mean level of PF 
stain 0.5 vs 1 on a scale of 0–2, P= 0.01) and slightly in PI (Ki-67 indices 8.2 vs 
3.1%, P = 0.11).  
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Of preoperative and biochemical factors, serum ionized calcium and PTH 
concentrations differed slightly in recurrent and non-recurrent PCs (1.86 (1.61–2.42) 
vs 1.72 (1.55–1.97) mmol/l, ( P = 0.20); and 1030 (358–2120) vs 904 (68–2220) 
ng/l, P = 0.41). 
Of all histological aspects assessed, vascular invasion was found in all recurrent 
PCs (and in 72% of non-recurrent PCs), and all tumors characterized with necrosis 
recurred. Significantly higher mitotic activity, the number of pathological mitoses, 
and more marked nuclear atypia (P < 0.05, P < 0.03 and P < 0.03, respectively), 









6.1 RADIONUCLIDE IMAGING BEFORE SURGICAL 
MANAGEMENT IN PHPT 
The first part of our study compares the accuracies of preoperative imaging 
techniques in primary and reoperation settings. 
6.1.1 IMAGING BEFORE PRIMARY SURGERY 
 
Surgery is the only definitive treatment for PHPT. Until the last few decades, a 
bilateral exploration under general anesthesia was the standard operation. The 
objectives of a parathyroidectomy are to achieve a long-lasting normocalcemia, and 
to provoke minimal complications with the shortest possible operation time. The 
development of preoperative imaging techniques and intraoperative tools has made 
focused parathyroidectomies possible. Despite the large number of studies regarding 
preoperative imaging in PHPT, there are still two schools of thought regarding the 
extent of preoperative imaging and parathyroidectomy techniques (Norman, Lopez 
& Politz 2012, Hindie et al. 2015, Minisola et al. 2016). However, a consensus exists 
that imaging studies are needed before parathyroidectomies (Bergenfelz et al. 2009, 
Hindie et al. 2009, Udelsman et al. 2014).  
In our study on scintigraphy methods before primary operation, the accuracy of 
123Iodine/99mTc-MIBI was clearly superior to that of 99mTc-MIBI: 63% vs. 34%, (P < 
0.001). Many previous studies (Tunninen et al. 2013, Caveny et al. 2012, Chen et al. 
1997, Hindie et al. 1998, Leslie et al. 2002, Philippon et al. 2014), but not all (Jorna 
et al. 2007) report similar findings. The European Association of Nuclear Medicine 
(EANM) guidelines and a recent review (Hindie et al. 2009, Hindie et al. 2015) 
recommend the use of a double-tracer method in scintigraphies. A recent study from 
the Mayo Clinic (Lee et al. 2016) reported a higher accuracy for planar 
123Iodine/99mTc-MIBI scintigraphy with a pinhole collimator compared to 99mTc-
MIBI SPECT or SPECT/CT. The use of a pinhole collimator, which improves the 
resolution and thus detects glands of unequal size, is also recommended by others 
(Hindie et al. 2015, Klingensmith et al. 2013).  
According to our study, the scintigraphy result had a crucial effect on the 
operation type. A quarter (23%) of patients with a localized tumor had a BNE, 
whereas 89% of those with negative scintigraphy had a BNE. We did not observe 
any significant difference in the outcome of surgery between the patients with 
positive and negative scintigraphies (92.7% vs 93.7%, respectively, P =NS). In 
contrast to our results, previous studies report a lower cure rate for patients with 
negative imaging studies (Allendorf et al. 2003, Bergenfelz et al. 2011). In nearly all 
operations not leading to normocalcemia, at least one pathological gland was 
removed and calcium decreased to near-normal levels.  
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One finding in 123Iodine/99mTc-MIBI was present in 193 (72%) of study patients. 
In 85% of these 193 patients, the imaging result was accurate. but 12 patients (6%) 
were not cured. The cure rate was lowest among those with bilateral 123Iodine/99mTc-
MIBI findings, with only 76.9% cured. Thus, a bilateral finding can be considered to 
be an operation failure risk. The factors contributing to positive imaging finding 
were concordant with other reports (Berber et al. 2008): higher serum calcium and 
PTH and gland weight were associated with a positive scintigraphy finding.  
Sixteen of the nineteen unsuccessful operations (84%) in the study were related 
to MGD. Of note, hereditary forms of PHPT were excluded from the study. 
According to the earlier literature, the vast majority (77%) of operation failures were 
due to undetected solitary adenomas (Udelsman 2011, Jaskowiak et al. 1996). The 
results of another recent study were in line with our results: 22% of the reoperations 
in the tertiary unit and 56% of patients operated elsewhere were related to an 
undetected single adenoma (Karakas et al. 2013). The overall proportion of MGD in 
our study, 15.7%, was similar to other studies (Lee et al. 2016, Minisola et al. 2016). 
Unfortunately, the cure rate for MGD was only 61%.  
In our study, the accuracies for a detection of a single adenoma and for MGD 
differed dramatically: 76% vs 15% for 123Iodine/99mTc-MIBI, and 42% vs 10% for 
99mTc-MIBI. In the meta-analysis, the sensitivities of 99mTc-MIBI for detecting a 
single adenoma and MGD, 88% and 45%, also differed markedly (Ruda, Hollenbeak 
& Stack 2005). Hyperplastic glands are smaller than adenomas and therefore more 
difficult to localize (Berber et al. 2008). Intraoperative localizing methods, IoPTH 
and a gamma probe are also at risk of missing hyperplastic glands (Hindie et al. 
2015, Siperstein et al. 2008). MGD continues to be a big challenge, and thus some 
have even returned to perform BNE on all patients (Norman, Lopez & Politz 2012). 
The duration of unilateral operations to one and two quandrants and of BNE were 
46, 52, and 68 minutes, respectively. Another study reported operation lengths of 78 
min for MIP and 144 min for BNE, and concluded that BNE was more expensive 
compared to focused parathyroidectomies with preoperative imaging (Lubitz et al. 
2012). Differences in pre- and intraoperative localizing methods and in the 
constitution of operation costs elsewhere and in our country make the cost-
effectiveness assessment difficult. 
Preoperative imaging studies provide valuable information to surgeons, but they 
must not be used as a diagnostic tool. However, these should be performed before 
every parathyroidectomy. As recommended by ESES, after two concordant imaging 
studies with sestamibi scintigraphy and ultrasound, a focused parathyroidectomy can 
be performed (Bergenfelz et al. 2009). A discordant finding should lead to either 
BNE or unilateral exploration with the use of IoPTH. Scintigraphies are able to 
reveal an ectopic gland, whereas ultrasound also provides information about the 
thyroid gland. Each institution must assess what is the most suitable algorithm to be 
used regarding localization and surgery strategies. The availability, the accuracies 
and the costs of different pre- and intraoperative localizing methods, the radiation 
exposure to the patient, as well as the local expertise regarding surgery, radiology, 
and nuclear medicine needs to be assessed (Hindie et al. 2015, Kunstman et al. 2013, 
Minisola et al. 2016). The Mayo Clinic chose to improve and continue to use planar 
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123Iodine/99mTc-MIBI scintigraphy and reserves SPECT or SPECT/CT for 
reoperations. In this clinic, ioPTH is used in all pararathyroidecomies (Lee et al. 
2016). In our institution, enlarged PHPT glands are localized by planar dual-phase 
123Iodine/99mTc-MIBI scintigraphy and ultrasound.  
6.1.2 PREOPERATIVE IMAGING BEFORE REOPERATION 
 
The majority of reoperations are related to persistent PHPT after primary operations. 
Recurrent PHPT, in which normal calcium and PTH concentrations are maintained 
for at least six months after surgery, is far less common than persistent disease and 
occurs mostly in familial PHPT. In addition, patients with previous non-parathyroid-
related neck surgery should be included in this challenging reoperation group 
(Udelsman 2011). 
Our study presents the preoperative imaging results of 21 patients in the 
reoperation setting. All underwent a planar 123Iodine/99mTc-MIBI scintigraphy and 
11C-methionine-PET/CT. SVS was performed on 18 and 99mTc-MIBI SPECT/CT on 
19 patients. The cure rate was 86%, in line with other studies (Ogilvie et al. 2006, 
Karakas et al. 2013). Two patients had the abnormal gland in mediastinum, and two 
others had an intrathyroideal parathyroid tumor. The accuracy of the 123Iodine/99mTc-
MIBI scan was 59%, slightly lower than in the primary operation setting but higher 
than that of 99mTc-MIBI SPECT/CT, which was only 19%. This is in line with other 
studies comparing these two imaging modalities (Lee et al. 2016, Tunninen et al. 
2013).  
SVS, an invasive localization method, has been a gold standard and used if other 
available noninvasive methods are negative. The sensitivity of SVS varies between 
71–90% (Kunstman et al. 2013), but the rate of false positives has been one of its 
disadvantages (Jones et al. 2002). The low accuracy of SVS in our study compared 
to 11C-methionine-PET/CT led to a marked decrease in using this method in our 
institution and the routine use of PET/CT as a second-line method in the reoperation 
setting.  
In our study, 11C-methionine-PET/CT had the highest accuracy, 65%. According 
to a meta-analysis of 14 studies on PET tracers in parathyroid localizing, the 
sensitivity of 11C-methionine-PET/CT was on average 77% and a PPV of 98% for 
detecting the pathological parathyroid in the correct quadrant (Kluijfhout et al. 
2016a). A recent study on 15 patients with previous neck operations and negative 
99mTc-MIBI SPECT/CT reported 11C-methionine-PET/CT to be positive in only six 
out of 15 (40%) patients. In five of them, operation findings correlated to the 
PET/CT findings (Traub-Weidinger et al. 2014). A series of 23 patients who were 
scheduled for a reoperation showed that the sensitivity of 11C-methionine-PET/CT in 
MGD was similar (30%) to 99mTc-MIBI SPECT/CT (Kluijfhout et al. 2016a, 
Hayakawa et al. 2015). In MGD, 11C-methionine PET/CT did not have an additional 
value (Hayakawa et al. 2015). Because of the reduced availability and the costs, 
PET/CT is suitable as a complimentary imaging modality (Hindie et al. 2015). In 
conclusion, 11C-methionine-PET/CT is a reliable second-line imaging modality with 
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only few false positives, but with false negatives related to MGD similarly to other 
modalities. 
The latest studies suggest that radiolabeled choline PET/CT might be a new 
tracer for localizing abnormal parathyroid glands. In a study of 24 PHPT patients, 
18F-fluorocholine PET/CT (FCH-PET/CT) had a PPV of 100%, a higher sensitivity 
(92% vs 64%), and a better performance in MGD compared to 99mTc-pertechnetate 
subtraction scintigraphy (Lezaic et al. 2014), in line with others (Kluijfhout et al. 
2015, Michaud et al. 2015). Disadvantages of this method are higher costs as well as 
possible false positives from thyroid nodules and inflammatory lymph nodes in the 
absence of a thyroid-specific tracer. Larger studies are needed, especially before 
reoperation or when conventional imaging remains negative or discordant (Hindie et 
al. 2015).  
Four-dimensional CT, available only in some centers, has been recommended 
even before primary operation when two imaging studies are discordant (Minisola et 
al. 2016), before reoperation, or in cases with mediastinal glands (Hindie et al. 2015, 
Udelsman 2011). 4D CTs should be used with caution in young patients as the 
radiation exposure (in average 10.4 mSv) to the thyroid area is high (Minisola et al. 
2016). Studied in 68 patients before reoperation, a regular MRI performed at 1.5 T in 
most patients, had a sensitivity of 82%, and a PPV of 85%. The sensitivity and PPV 
of 23 patients before primary operation were lower, only 64% and 67%, respectively 
(Grayev et al. 2012, Kluijfhout et al. 2016b). In some cases, MRI can provide 
additional information if other imaging methods remain negative (Kluijfhout et al. 
2016b). 
Of the latest modalities, 18F-fluorocholine-PET/CT seems an interesting option 
for patients with discordant imaging. Thus far it has only been studied in a primary 
operation setting, but the sensitivity and specificity are better than those of planar 
123Iodine/99mTc-MIBI or 99mTc-MIBI SPECT/CT (Lezaic et al. 2014). There is 
preliminary data on 18F-fluorocholine-PET combined with MRI and this seems to be 
useful in patients with negative or discordant imaging studies (Kluijfhout et al. 
2016a). 
Intraoperative PTH, recommended in all reoperations (Bergenfelz et al. 2009, 
Udelsman 2011), was not available in these operations. The 21 patients in our study 
did not have any postoperative complications, which suggests slightly better results 
compared to other studies reporting 9% for permanent recurrent laryngeal nerve 
palsy (Karakas et al. 2013). In addition to good expertise in preoperative imaging, 
successful reoperations require an experienced surgeon.  
According to ESES guidelines and recent reviews, two concordant imaging 
studies (a sestamibi scintigraphy, preferably with SPECT or double-tracer, and 
ultrasound) are performed before reoperation. If these are discordant or negative, the 
second-line options include 4-dimensional CT, ultrasound-guided thin-needle 
biopsy, MRI, and PET/CT, depending on the availability (Bergenfelz et al. 2009, 
Hindie et al. 2015, Kunstman et al. 2013). SVS is used if results are inconclusive. If 
a positive or suggestive result is obtained, surgery is possible. IoPTH is 
recommended for all reoperations. For appropriate patients with negative imaging, 
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surgery can be performed in a primary operation setting. Others are offered the best 
possible medical therapy (Kunstman et al. 2013). 
6.2 HEALTH-RELATED QUALITY OF LIFE IN PHPT 
The third part of the present study compared the preoperative HRQoL of PHPT 
patients referred to surgery to the Finnish control population standardized for gender 
and age (n=4295). The HRQoL questionnaire is a tool to assess those symptoms 
otherwise difficult-to-measure but necessary-to-evaluate in PHPT. Twenty percent of 
patients did not fulfill the criteria for surgery. Nearly 41% of the study patients 
complained of possibly PHPT-related symptoms. We followed these patients’ 
HRQoL postoperatively for 12 months and compared it to preoperative HRQoL 
results and to the control group.  
15D. We used the Finnish, well-validated and generic 15D instrument (Saarni et 
al. 2006, Kontodimopoulos et al. 2012) instead of disease-specific questionnaires to 
be able to compare the results with those of the large Finnish age- and gender-
standardized control group from the national Health 2011 project (Saarni, Luoma & 
Koskinen 2012). 15D gives a single score and a profile of 15 dimension to describe 
HRQoL. The SF-36 questionnaire, used in the three prospective, randomized studies 
on mild PHPT (Ambrogini et al. 2007, Bollerslev et al. 2007, Rao et al. 2004), 
evaluates HRQoL with two values and a profile. Therefore, SF-36 can not assess or 
compare the overall effect of the changes to HRQoL (Sintonen 2013).  
Preoperative HRQoL. In this study, the preoperative HRQoL was markedly 
lower than in the general population and a significant difference was present in 13 of 
15 dimensions. The five dimensions (mental function, discomfort and symptoms, 
depression, distress, and vitality) measuring cognitive and psychiatric well-being 
differed the most from the general population. Deterioration in moving, speech and 
breathing can be explained by altered muscle function. That seen in excretion may 
be related to polyuria. A decrease in sexual activity might reflect dissatisfaction in 
overall well-being. The lower score in seeing remains unexplained. Only hearing and 
eating did not differ from the sample of the general population.  
The preoperative HRQoL was lower in those with a higher amount of regular 
medications, was also previously reported to decrease HRQoL (Andersson, 
Marcusson & Wressle 2014), and in those who preoperatively complained of 
possibly PHPT-related symptoms. In this study, the number of regular medications 
describes the burden of possible comorbidities.  
Postoperative HRQoL. During the first six postoperative months, HRQoL 
improved in 10 of 15 dimensions, and in one more dimension during the next six 
months near to the normal level of the controls. The recent data from our PHPT 
cohort after a mean follow-up time of 3.3 years after surgery confirms that the 
improvement in HRQoL is postoperationally sustained (Storvall et al., unpublished 
data). Of the 13 preoperatively impaired dimensions, only those of seeing and 
breathing remained unchanged. When converted to the GAS scale, which estimates 
the minimal important change of HRQoL (Alanne et al. 2015), 77% of the cohort 
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showed a clinically important improvement. The change in HRQoL was similar 
between those fulfilling and not fulfilling the surgery criteria and between those with 
and without possible symptoms. Only a higher educational level and a lower 
preoperative 15D score, both known to affect the improvement of HRQoL after 
interventions (Torvinen et al. 2013), increased the improvement in HRQoL.  
There is consensus based on several studies that HRQoL is decreased in PHPT, 
and even in mild PHPT (Weber et al. 2013, Pasieka et al. 2002, Burney et al. 1999, 
Caillard et al. 2007, Dulfer et al. 2016). According to Weber et al. (Weber et al. 
2013), 22% of PHPT patients reported having suicidal ideation, twice as much as in 
the control group. This proportion decreased to 10% one year after surgery. The 
studies show that PHPT is associated with cognitive disturbances and psychological 
symptoms (Babinska et al. 2012, Walker et al. 2009, Roman et al. 2011b). The three 
prospective, randomized studies on PHPT patients who did not fulfill the current 
surgical criteria randomized patients into observation and surgery subgroups and 
used the SF-36 questionnaire in the follow-up. Two of these (Ambrogini et al. 2007, 
Rao et al. 2004) showed improvement in HRQoL. The largest of these, on 191 PHPT 
patients not fulfilling the surgery criteria, showed impaired HRQoL preoperatively 
without any postoperative change in the surgery group. However, a meta-analysis 
combined these three studies and concluded an overall improvement in mild PHPT 
(Cheng et al. 2015). Smaller patient groups in other studies (Blanchard et al. 2014, 
Caillard et al. 2007) have shown a postoperatively improved impairment of HRQoL 
in PHPT patients, which did not meet the surgery criteria. Unfortunately, both of 
these lacked a control group. In addition, neurocognitive symptoms, depression, and 
anxiety improve postoperatively (Babinska et al. 2012, Walker et al. 2009, Roman et 
al. 2011a). 
We did not find any correlation between calcium concentration or PTH 
concentration and preoperative levels or improvement in HRQoL. The correlation 
between calcium and the improvement of HRQoL has been found in some (Weber et 
al. 2013, Blanchard et al. 2014, Sheldon et al. 2002), but not all cohorts (Burney et 
al. 1999, Gopinath, Sadler & Mihai 2010).  
The limitation of our study was the lack of non-operated controls with PHPT. It 
was not possible to count the number of patients to whom the information letter and 
first 15D questionnaire was sent. Nearly all those (94%) who replied to the first 
questionnaire also responded to the two subsequent questionnaires. 
Most existing data suggests that HRQoL is decreased in PHPT (Silverberg et al. 
2014). HRQoL should be evaluated, especially in PHPT patients without obvious 
surgery criteria, as it may give additional information in decision-making. This study 
now shows that the 15D questionnaire detects the changes in the state of health 
related to PHPT. The distinct 15D profile shown in PHPT patients demonstrates 
deterioration, especially in dimensions of mental well-being. SF-36 includes 
questions related to pain (often absent in PHPT), anxiety, and depression, whereas 
15D asks about discomfort and symptoms which also include nausea or other types 
of discomfort. The question of mental function in 15D asks about fatigue and 
memory loss, both typical for PHPT. Vitality and usual activities are both clearly 
reduced in PHPT. The use of the 15D questionnaire requires specific software and 
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briefing of staff. However, the age- and gender-matched general population provides 
reference levels for HRQoL in 15D. An easy-to-use disease-specific tool of 16 
questions, Primary Hyperparathyroidism Quality of Life (PHPQoL), was recently 
introduced. PHPQoL correlated with the SF-36 in a prospective, case control study 
in PHPT. PHPQoL showed both lower HRQoL for patients fulfilling the 
international surgery criteria compared to those for whom surveillance was planned, 
and an improvement in HRQoL at a one-year follow-up after surgery (Webb et al. 
2016). However, HRQoL is affected by the person’s gender and age, and PHPQoL 
lacks the comparison to general population.  
The effect of parathyroidectomy on HRQoL is a subject of debate. However, the 
majority of studies have observed a change in HRQoL after operation (Ambrogini et 
al. 2007, Weber et al. 2013, Caillard et al. 2007, Dulfer et al. 2016). Serum calcium 
concentration is considered a criterion for surgery. As serum calcium seems not to 
correlate with HRQoL or symptoms, some patients with only mild hypercalcemia 
may suffer from PHPT-related symptoms. It is often impossible to be certain 
whether a patient’s symptoms are related to PHPT and whether the extent of 
discomfort and the decrease in HRQoL allows a surgical intervention to be 
performed. However, the improvement in the 15D score after parathyroidectomy in 
PHPT is among the largest described by 15D after interventions, and is at least 
similar to that after primary hip replacement or obesity surgery (Helmio et al. 2011, 
Rasanen et al. 2007). Cinacalcet treatment decreases serum calcium concentrations 
(Marcocci et al. 2009). It can be used temporarily to normalize serum calcium in 
order to relieve possible symptoms. More medical intervention studies on this topic 
are needed (Grant, Velusamy 2014). 
6.3 PARATHYROID CARCINOMA IN FINLAND  
Incidence. Our study presents a nationwide cohort of PC from 2000 to 2011, with 32 
new cases of PC. We also demonstrate a highly significant increase in the incidence 
of PC during the last 20 years in Finland. Similar increases in the same time period 
have been reported in the United States and Australia (Brown et al. 2011, Lee et al. 
2007). The incidence of PHPT has increased through the wider use of serum calcium 
measurements, and pathologic diagnostics have improved (Bilezikian et al. 2016). 
However, it is unlikely that these aspects explain all the change.  
The clinical presentation. PC patients more often experienced a renal or bone 
involvement in PHPT and especially both of these (28%). Nearly half (44%) of our 
PC patients had a hypercalcemic crisis before diagnosis. As seen in other PC cohorts 
(Cetani, Pardi & Marcocci 2016, Harari et al. 2011, Villar-del-Moral et al. 2014, 
Marcocci et al. 2008), a third of patients also had a parathyroid adenoma diagnosed 
either before the PC or at follow-up. In APA patients, the clinical presentation was 
milder regarding renal and bone manifestations and hypercalcemic crises. Only 4% 
had a parathyroid adenoma at the end of FU. The calcium concentration in PC, APA, 
and PA were 1.76, 1.56 and 1.44 mmol/l, respectively. Serum PTH and creatinine 
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levels showed similar tendencies in subgroups. This is concordant with other 
comparisons of APA and PC (Quinn et al. 2015). 
Histology. All our PC patients had a confirmed invasion, capsular in 72%, 
vascular in 72%, and perineural in 9% of patients. Signs of proliferation (the mitotic 
activity, nuclear atypia) were documented more often in the PC than the APA group. 
In PCs, chief cells and diffuse growth type dominated in 88% and 75%, respectively. 
Necrosis was present in 9% of PCs but absent in APAs. Fibrous septae and 
hemosiderin deposits were a common finding in both the APA and the PC group. 
The WHO criteria for PC include capsular invasion (Bondeson et al. 2004). It should 
be distinguished from “pseudocapsular” invasion, where tumor cells are trapped 
within the capsule (Cetani, Pardi & Marcocci 2016). We confirmed the diagnosis of 
PC and consequently some PCs were transferred to the APA group if the tumor 
invasion was not unequivocal. The difficulty of the evaluation of the invasion is 
shown in the recent study comparing PCs and APAs (Quinn et al. 2015). In the 
subgroups of APA, based on the original diagnosis, the re-evaluation showed 
invasion of surrounding tissues, and capsular and vascular invasion in 21%, 56%, 
and 9% of cases, respectively.  
We performed parafibromin and Ki-67 stainings for all tissue samples using the 
TMA technique. We used a scale of negative, intermediate, and completely positive 
for parafibromin. Overall, parafibromin stain was weaker in PCs but negative in only 
13% of PCs compared to 4% in APAs and 0% in adenomas. According to previous 
studies, parafibromin is negative in 32–46% of PCs (Fernandez-Ranvier et al. 2007, 
Truran et al. 2014). None of the parafibromin positive APAs or PCs recurred 
similarly to others (Kruijff et al. 2014). The TMA technique, which was used to 
assess only a few spots of the tissue specimen, resulted with lower PIs than 
originally, when the whole sample was assessed. However, these values correlated, 
and the median Ki-67 for PCs in the original evaluation was 5%. Ki-67 is over 5% in 
21–60% of PC samples (Fernandez-Ranvier et al. 2007, Truran et al. 2014). Ki-67 
was significantly lower in the APA than in PC group, but the values overlapped.  
Because the parathyroids are surrounded by a thin capsule and vital organs, the 
enlarged glands are enucleated without any tumor margins. The challenging 
differential diagnosis between APA and PC would benefit, if possible, from larger 
tumor margins. The distinction between PC and APA is of critical importance in 
evaluating the risk of recurrence and determining the appropriate extent of surgery 
and the length of follow-up.  
The cell division cycle’s (CDC73) germline gene status was available in 56% of 
PC and 57% of APA study patients. According to the literature, the prevalence of 
this gene mutation in PC varies between 15% and 70% of cases (Cetani, Pardi & 
Marcocci 2016). In our study, only 6% and 6% of PCs and APAs, respectively, had a 
mutation in this gene. The PC patient with the CDC73 mutation was an 18-year old 
male who had a strong family history of PHPT associated with PC, caused by a 
deletion of the CDC73 gene demonstrated in several affected family members 
(Korpi-Hyövälti et al. 2014). Our nationwide PC cohort seems to also include 
CDC73-mutation negative PCs that are possibly related to better survival and less 
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recurrences than in earlier reports (Cetani, Pardi & Marcocci 2016, Harari et al. 
2011).  
Treatments and prognosis Half (47%) of PCs underwent an en bloc resection 
compared to 18% in the APA group, and a local parathyroidectomy was performed 
on others. The PC tumors were larger than the APA tumors, in line with that 
previously reported (Quinn et al. 2015). En bloc resection including at least a tumor 
resection with a sufficient margin, and the removal of the ipsilateral thyroid lobe, 
recommended when there is a suspicion of PC (Cetani, Pardi & Marcocci 2016, 
Talat, Schulte 2010, Schulte et al. 2014), is important to ensure sufficient tumor 
margins in PCs and to improve the assessment of local/capsular invasion. Schulte et 
al. even suggest (Schulte et al. 2010) the dissection of the centrocervical lymph node 
compartment in all patients. 
The PC patients in our study underwent an average of two neck operations. 
Recurrences were observed in six (21%) patients, five of whom developed 
metastasis. The only recurrence of APA was in a man with a CDC73-mutation. The 
very low recurrence rate during FU suggests an accurate diagnosis of APA in our 
cohort. In some PC patients, the reoperation for recurrent hypercalcemia revealed a 
benign adenoma, not the PC. Cumulative amounts of persistent hypocalcemia and 
laryngeal nerve palsy were 22% and 22% less, respectively, than in another report 
(Harari et al. 2011). Every fifth patient received radiotherapy and 13% received 
chemotherapy. Interestingly, the impaired renal function seen only in the PC group 
did not improve during the FU. The 5- and 10-year survival rates were 91% and 72% 
in our study. This is in line with one study (Villar-del-Moral et al. 2014) but is much 
better than others reported (Harari et al. 2011). Of 32 PCs, four died of the disease at 
nearly four years in the FU. The patients in our study and that of Villar-del-Moral 
were diagnosed and treated rather recently, and the lower recurrence rate and 
mortality may reflect an improvement in prognosis.  
Factors associated with recurrent PC. Tumors with lymph node metastasis or 
invasion to surrounding organs (trachea and muscle) at diagnosis recurred. The three 
tumors with necrosis at histological evaluation also recurred. All recurrent tumors 
had vascular invasion at diagnosis, which is considered an important factor for 
recurrence (Talat, Schulte 2010, Schulte et al. 2012). In line with most previous 
studies (Talat, Schulte 2010, Villar-del-Moral et al. 2014, Sadler et al. 2014), but not 
all (Asare et al. 2015), tumor size was not associated with recurrence. Histological 
features of proliferations were significantly more common in recurrent tumors. 
Schulte et al. have introduced two staging systems: Schulte A divides PCs into 
stages I to IV, whereas Schulte B consists of low-risk and high-risk groups. The 
latter consists of PCs with vascular invasion, invasion to vital organs (not soft 
tissue), lymph node or distant metastasis. The pilot cohort of Schulte et al. (Schulte 
et al. 2012) and three others (Talat, Schulte 2010, Villar-del-Moral et al. 2014, 
Sadler et al. 2014) used these stagings for their PC cohorts. The higher Schulte risk 
groups had more recurrences and higher risk of death. All recurrent PCs in our study 
would belong to the high-risk group in Schulte B. In Schulte A, three would be Stage 
II (vascular invasion) and three Stage III (positive lymph nodes and invasion to 
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trachea). Of the non-recurrent PCs, 74% had vascular invasion and those would also 
belong to the Schulte A high-risk group.  
Our study suggests that PC should suspected in patients with serum ionized 
calcium over 1.70mmol/l and especially both renal and bone manifestations of 
PHPT. Intraoperative decision-making by an experienced endocrine surgeon plays a 
major role in performing an appropriate procedure decreasing recurrence rates. 
Tumor invasion to surrounding vital organs or lymph node metastasis seems to 
represent an increased recurrence risk in a similar way to signs of proliferation or 
necrosis, negative parafibromin staining and Ki67 over 5%. Immunohistochemical 
markers, or a combination of clinical and histological features, may provide a tool 




7 CONCLUSION AND FUTURE PROSPECTS 
The first part of this study shows that the dual-phase double-tracer scintigraphy with 
123Iodine and 99mTc-MIBI is superior to dual-phase 99mTc-MIBI scintigraphy. 
According to the related literature, this 123Iodine/99mTc-MIBI scan is also the 
scintigraphy of choice before primary operation. In primary operations, 84% of 
operation failures were due to MGD being present in 15.6% of patients. The use of 
dual-tracer scintigraphy has improved the imaging of parathyroids. However, 
additional tools, such as the use of intraoperative PTH measurement, might be of 
further benefit. 
Patients with persistent or recurrent PHPT and those with previous non-thyroid-
related neck operations need two concordant imaging results before reoperation. If 
ultrasound and scintigraphy are discordant or negative, we suggest the use of 11C-
methionine-PET/CT instead of SVS as a second-line technique. A future technique 
may be choline PET for challenging cases combined with CT or MRI. IoPTH or a 
gamma probe can also help to locate the enlarged gland intraoperatively.  
The HRQoL in PHPT is decreased and improves after surgery at a rate close to 
control population level at one-year follow-up. The dimension profile of 15D is able 
to describe the symptoms of mild PHPT. As serum calcium did not correlate to the 
HRQoL in PHPT, PHPT-related symptoms are possible in mild PHPT. The non-
specific symptoms of PHPT and HRQoL require close questioning and warrant 
being objectively measured in an out-patient clinic. Prospective case control studies 
on the benefits of cinacalcet in improving the PHPT-related symptoms might offer 
further information on the use of this medication in inoperable PHPT. 
The incidence of parathyroid carcinoma has markedly increased in Finland. The 
clinical and histological presentation of our cohort of 32 PC patients diagnosed in 
Finland between 2000 and 2011 is similar to previous reports. However, the 
recurrence rate and mortality were lower than in most earlier reports, suggesting that 
the prognosis of PC might be improving. Atypical adenomas represent a borderline 
type of parathyroid tumor, sharing properties with both benign adenomas and PCs, 
but signs of invasion are lacking. Of 28 APAs, the only recurrence was in a patient 
with CDC73-mutation. This mutation may be assessed in the most aggressive cases 
of both PCs and APAs. Recurrence risk seems higher in patients with vital organ or 
lymph node invasion at diagnosis, negative parafibromin stain, or tumor necrosis. 
All recurrent cases also presented with vascular invasion. According to our study, 
PC should be suspected in patients with serum ionized calcium over 1.70 mmol/l. 
Further studies on the use of immunohistochemical markers in differential diagnosis 
or in the recurrence risk assessment are needed. Assessment of the risk for PC by 
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QUALITY OF LIFE QUESTIONNAIRE (15D©)  
Please read through all the alternative responses to each question before placing a cross (x) against the 
alternative which best describes your present health status. Continue through all 15 questions in this 
manner, giving only one answer to each.  
QUESTION 1. MOBILITY  
1 ( ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs.  
2 ( ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight 
difficulties.  
3 ( ) I am able to walk without help indoors (with or without an appliance), but outdoors and/or on 
stairs only with considerable difficulty or with help from others.  
4 ( ) I am able to walk indoors only with help from others.  
5 ( ) I am completely bed-ridden and unable to move about.  
QUESTION 2. VISION  
1 ( ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or without 
glasses).  
2 ( ) I can read papers and/or TV text with slight difficulty (with or without glasses).  
3 ( ) I can read papers and/or TV text with considerable difficulty (with or without glasses).  
4 ( ) I cannot read papers or TV text either with glasses or without, but I can see enough to walk about 
without guidance.  
5 ( ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind.  
QUESTION 3. HEARING  
1 ( ) I can hear normally, i.e. normal speech (with or without a hearing aid).  
2 ( ) I hear normal speech with a little difficulty.  
3 ( ) I hear normal speech with considerable difficulty; in conversation I need voices to be louder than 
normal.  
4 ( ) I hear even loud voices poorly; I am almost deaf.  
5 ( ) I am completely deaf.  
QUESTION 4. BREATHING  
1 ( ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty.  
2 ( ) I have shortness of breath during heavy work or sports, or when walking briskly on flat ground 
or slightly uphill.  
3 ( ) I have shortness of breath when walking on flat ground at the same speed as others my age.  
4 ( ) I get shortness of breath even after light activity, e.g. washing or dressing myself.  
5 ( ) I have breathing difficulties almost all the time, even when resting.  
QUESTION 5. SLEEPING  
1 ( ) I am able to sleep normally, i.e. I have no problems with sleeping. 




3 ( ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept enough. 
4 ( ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely, or 
usually waking at night and/or too early in the morning. 
5 ( ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of sleeping pills, 
or staying awake most of the night.  
QUESTION 6. EATING  
1( ) I am able to eat normally, i.e. with no help from others. 
2 ( ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with special 
appliances).  
3 ( ) I need some help from another person in eating.  
4 ( ) I am unable to eat by myself at all, so I must be fed by another person.  
5 ( ) I am unable to eat at all, so I am fed either by tube or intravenously.  
QUESTION 7. SPEECH  
1 ( ) I am able to speak normally, i.e. clearly, audibly and fluently.  
2 ( ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or changes of 
pitch.  
3 ( ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or 
stammering.  
4 ( ) Most people have great difficulty understanding my speech.  
5 ( ) I can only make myself understood by gestures.  
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QUESTION 8. ELIMINATION  
1 ( ) My bladder and bowels work normally and without problems.  
2 ( ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with urination, or 
loose or hard bowels.  
3 ( ) I have marked problems with my bladder and/or bowel function, e.g. occasional 'accidents', or 
severe constipation or diarrhea.  
4 ( ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents', or need 
of catheterization or enemas.  
5 ( ) I have no control over my bladder and/or bowel function.  
QUESTION 9. USUAL ACTIVITIES  
1 ( ) I am able to perform my usual activities (e.g. employment, studying, housework, free-time 
activities) without difficulty.  
2 ( ) I am able to perform my usual activities slightly less effectively or with minor difficulty.  
3 ( ) I am able to perform my usual activities much less effectively, with considerable difficulty, or 
not completely.  
4 ( ) I can only manage a small proportion of my previously usual activities.  
5 ( ) I am unable to manage any of my previously usual activities.  
QUESTION 10. MENTAL FUNCTION  
1 ( ) I am able to think clearly and logically, and my memory functions well. 
2 ( ) I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me.  
3 ( ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat 
impaired.  
4 ( ) I have great difficulties in thinking clearly and logically, or my memory is seriously impaired.  
5 ( ) I am permanently confused and disoriented in place and time.  
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QUESTION 11. DISCOMFORT AND SYMPTOMS  
1 ( ) I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.  
2 ( ) I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.  
3 ( ) I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.  
4 ( ) I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.  
5 ( ) I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc.  
QUESTION 12. DEPRESSION  
1 ( ) I do not feel at all sad, melancholic or depressed.  
2 ( ) I feel slightly sad, melancholic or depressed. 
3 ( ) I feel moderately sad, melancholic or depressed.  
4 ( ) I feel very sad, melancholic or depressed.  
5 ( ) I feel extremely sad, melancholic or depressed.  
QUESTION 13. DISTRESS  
1 ( ) I do not feel at all anxious, stressed or nervous.  
2 ( ) I feel slightly anxious, stressed or nervous. 
3 ( ) I feel moderately anxious, stressed or nervous.  
4 ( ) I feel very anxious, stressed or nervous.  
5 ( ) I feel extremely anxious, stressed or nervous.  
QUESTION 14. VITALITY  
1 ( ) I feel healthy and energetic.  
2 ( ) I feel slightly weary, tired or feeble.  
3 ( ) I feel moderately weary, tired or feeble.  
4 ( ) I feel very weary, tired or feeble, almost exhausted.  
5 ( ) I feel extremely weary, tired or feeble, totally exhausted.  
QUESTION 15. SEXUAL ACTIVITY  
1 ( ) My state of health has no adverse effect on my sexual activity.  
2 ( ) My state of health has a slight effect on my sexual activity. 
3 ( ) My state of health has a considerable effect on my sexual activity.  
4 ( ) My state of health makes sexual activity almost impossible.  
5 ( ) My state of health makes sexual activity impossible.  
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TERVEYTEEN LIITTYVÄN ELÄMÄNLAADUN KYSELYLOMAKE (15D©)/Harri Sintonen 
(in Finnish)  
Ohje: Lukekaa ensin läpi huolellisesti kunkin kysymyksen kaikki vastausvaihtoehdot. Merkitkää 
sitten rasti (x) sen vaihtoehdon kohdalle, joka parhaiten kuvaa nykyistä terveydentilaanne. 
Menetelkää näin kaikkien kysymysten 1-15 kohdalla. Kustakin kysymyksestä rastitetaan siis yksi 
vaihtoehto.  
KYSYMYS 1. Liikuntakyky  
1() Pystyn kävelemään normaalisti (vaikeuksitta) sisällä, ulkona ja portaissa.  
2() Pystyn kävelemään vaikeuksitta sisällä, mutta ulkona ja/tai portaissa on pieniä vaikeuksia.  
3() Pystyn kävelemään ilman apua sisällä (apuvälinein tai ilman), mutta ulkona ja/tai portaissa 
melkoisin vaikeuksin tai toisen avustamana.  
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4() Pystyn kävelemään sisälläkin vain toisen avustamana.  
5() Olen täysin liikuntakyvytön ja vuoteenoma.  
KYSYMYS 2. Näkö  
1 ( ) Näen normaalisti eli näen lukea lehteä ja TV:n tekstejä vaikeuksitta (silmälaseilla tai ilman).  
2 ( ) Näen lukea lehteä ja/tai TV:n tekstejä pienin vaikeuksin (silmälaseilla tai ilman).  
3 ( ) Näen lukea lehteä ja/tai TV:n tekstejä huomattavin vaikeuksin (silmälaseilla tai ilman).  
4 ( ) En näe lukea lehteä enkä TV:n tekstejä ilman silmälaseja tai niiden kanssa, mutta näen kulkea 
ilman opasta.  
5 ( ) En näe lukea oppaatta eli olen lähes tai täysin sokea.  
KYSYMYS 3. Kuulo  
1 ( ) Kuulen normaalisti eli kuulen hyvin normaalia puheääntä (kuulokojeella tai ilman).  
2 ( ) Kuulen normaalia puheääntä pienin vaikeuksin.  
3 ( ) Minun on melko vaikea kuulla normaalia puheääntä, keskustelussa on käytettävä normaalia 
kovempaa puheääntä.  
4 ( ) Kuulen kovaakin puheääntä heikosti; olen melkein kuuro.  
5 ( ) Olen täysin kuuro.  
KYSYMYS 4. Hengitys  
1 ( ) Pystyn hengittämään normaalisti eli minulla ei ole hengenahdistusta eikä muita 
hengitysvaikeuksia. 
2 ( ) Minulla on hengenahdistusta raskaassa työssä tai urheillessa, reippaassa kävelyssä tasamaalla tai 
lievässä ylämäessä.  
3 ( ) Minulla on hengenahdistusta, kun kävelen tasamaalla samaa vauhtia kuin muut ikäiseni.  
4 ( ) Minulla on hengenahdistusta pienenkin rasituksen jälkeen, esim. peseytyessä tai pukeutuessa.  
5 ( ) Minulla on hengenahdistusta lähes koko ajan, myös levossa.  
KYSYMYS 5. Nukkuminen  
1 ( ) Nukun normaalisti eli minulla ei ole mitään ongelmia unen suhteen.  
2 ( ) Minulla on lieviä uniongelmia, esim. nukahtamisvaikeuksia tai satunnaista yöheräilyä.  
3 ( ) Minulla on melkoisia uniongelmia, esim. nukun levottomasti tai uni ei tunnu riittävältä.  
4 ( ) Minulla on suuria uniongelmia, esim. joudun käyttämään usein tai säännöllisesti unilääkettä, 
herään säännöllisesti yöllä ja/tai aamuisin liian varhain.  
5 ( ) Kärsin vaikeasta unettomuudesta, esim. unilääkkeiden runsaasta käytöstä huolimatta 
nukkuminen on lähes mahdotonta, valvon suurimman osan yöstä.  
KYSYMYS 6. Syöminen  
1 ( ) Pystyn syömään normaalisti eli itse ilman mitään vaikeuksia.  
2 ( ) Pystyn syömään itse pienin vaikeuksin (esim. hitaasti, kömpelösti, vavisten tai 
erityisapuneuvoin).  
3 ( ) Tarvitsen hieman toisen apua syömisessä.  
4 ( ) En pysty syömään itse lainkaan, vaan minua pitää syöttää.  
5 ( ) En pysty syömään itse lainkaan, vaan minulle pitää antaa ravintoa letkun avulla tai 
suonensisäisesti.  
KYSYMYS 7. Puhuminen  
1 ( ) Pystyn puhumaan normaalisti eli selvästi, kuuluvasti ja sujuvasti.  
2 ( ) Puhuminen tuottaa minulle pieniä vaikeuksia, esim. sanoja on etsittävä tai ääni ei ole riittävän 
kuuluva tai se vaihtaa korkeutta.  
3 ( ) Pystyn puhumaan ymmärrettävästi, mutta katkonaisesti, ääni vavisten, sammaltaen tai änkyttäen.  
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4 ( ) Muilla on vaikeuksia ymmärtää puhettani.  
5 ( ) Pystyn ilmaisemaan itseäni vain elein.  
KYSYMYS 8. Eritystoiminta  
1 ( ) Virtsarakkoni ja suolistoni toimivat normaalisti ja ongelmitta.  
2 ( ) Virtsarakkoni ja/tai suolistoni toiminnassa on lieviä ongelmia, esim. minulla on 
virtsaamisvaikeuksia tai kova tai löysä vatsa  
3 ( ) Virtsarakkoni ja/tai suolistoni toiminnassa on melkoisia ongelmia, esim. minulla on satunnaisia 
virtsanpidätysvaikeuksia tai vaikea ummetus tai ripuli.  
4 ( ) Virtsarakkoni ja/tai suolistoni toiminnassa on suuria ongelmia, esim. minulla on säännöllisesti 
"vahinkoja" tai peräruiskeiden tai katetroinnin tarvetta.  
5 ( ) En hallitse lainkaan virtsaamista ja/tai ulostamista.  
KYSYMYS 9. Tavanomaiset toiminnot  
1 ( ) Pystyn suoriutumaan normaalisti tavanomaisista toiminnoista (esim. ansiotyö, opiskelu, kotityö, 
vapaa-ajan toiminnot).  
2 ( ) Pystyn suoriutumaan tavanomaisista toiminnoista hieman alentuneella teholla tai pienin 
vaikeuksin.  
3 ( ) Pystyn suoriutumaan tavanomaisista toiminnoista huomattavasti alentuneella teholla tai 
huomattavin vaikeuksin tai vain osaksi.  
4 ( ) Pystyn suoriutumaan tavanomaisista toiminnoista vain pieneltä osin.  
5 ( ) En pysty suoriutumaan lainkaan tavanomaisista toiminnoista.  
KYSYMYS 10. Henkinen toiminta  
1 ( ) Pystyn ajattelemaan selkeästi ja johdonmukaisesti ja muistini toimii täysin moitteettomasti.  
2 ( ) Minulla on lieviä vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai muistini ei toimi täysin 
moitteettomasti  
3 ( ) Minulla on melkoisia vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai minulla on jonkin 
verran muistin menetystä  
4 ( ) Minulla on suuria vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai minulla on huomattavaa 
muistin menetystä  
5 ( ) Olen koko ajan sekaisin ja vailla ajan tai paikan tajua  
KYSYMYS 11. Vaivat ja oireet  
1 ( ) Minulla ei ole mitään vaivoja tai oireita, esim. kipua, särkyä, pahoinvointia, kutinaa jne.  
2 ( ) Minulla on lieviä vaivoja tai oireita, esim. lievää kipua, särkyä, pahoinvointia, kutinaa jne.  
3 ( ) Minulla on melkoisia vaivoja tai oireita, esim. melkoista kipua, särkyä, pahoinvointia, kutinaa 
jne.  
4 ( ) Minulla on voimakkaita vaivoja tai oireita, esim. voimakasta kipua, särkyä, pahoinvointia, 
kutinaa jne.  
5 ( ) Minulla on sietämättömiä vaivoja ja oireita, esim. sietämätöntä kipua, särkyä, pahoinvointia, 
kutinaa jne.  
KYSYMYS 12. Masentuneisuus  
1 ( ) En tunne itseäni lainkaan surulliseksi, alakuloiseksi tai masentuneeksi.  
2 ( ) Tunnen itseni hieman surulliseksi, alakuloiseksi tai masentuneeksi.  
3 ( ) Tunnen itseni melko surulliseksi, alakuloiseksi tai masentuneeksi.  
4 ( ) Tunnen itseni erittäin surulliseksi, alakuloiseksi tai masentuneeksi.  
5 ( ) Tunnen itseni äärimmäisen surulliseksi, alakuloiseksi tai masentuneeksi.  
KYSYMYS 13. Ahdistuneisuus  
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1 ( ) En tunne itseäni lainkaan ahdistuneeksi, jännittyneeksi tai hermostuneeksi.  
2 ( ) Tunnen itseni hieman ahdistuneeksi, jännittyneeksi tai hermostuneeksi.  
3 ( ) Tunnen itseni melko ahdistuneeksi, jännittyneeksi tai hermostuneeksi.  
4 ( ) Tunnen itseni erittäin ahdistuneeksi, jännittyneeksi tai hermostuneeksi.  
5 ( ) Tunnen itseni äärimmäisen ahdistuneeksi, jännittyneeksi tai hermostuneeksi.  
KYSYMYS 14. Energisyys  
1 ( ) Tunnen itseni terveeksi ja elinvoimaiseksi.  
2 ( ) Tunnen itseni hieman uupuneeksi, väsyneeksi tai voimattomaksi.  
3 ( ) Tunnen itseni melko uupuneeksi, väsyneeksi tai voimattomaksi.  
4 ( ) Tunnen itseni erittäin uupuneeksi, väsyneeksi tai voimattomaksi, lähes "loppuun palaneeksi".  
5 ( ) Tunnen itseni äärimmäisen uupuneeksi, väsyneeksi tai voimattomaksi, täysin "loppuun 
palaneeksi".  
KYSYMYS 15. Sukupuolielämä  
1 ( ) Terveydentilani ei vaikeuta mitenkään sukupuolielämääni.  
2 ( ) Terveydentilani vaikeuttaa hieman sukupuolielämääni.  
3 ( ) Terveydentilani vaikeuttaa huomattavasti sukupuolielämääni.  
4 ( ) Terveydentilani tekee sukupuolielämäni lähes mahdottomaksi.  




PRIMAARI HYPERPARATYREOOSI JA ELÄMÄNLAATU –TUTKIMUS 
 
Kysymme tämän ensimmäisen elämänlaatukyselyn yhteydessä joitakin tarkentavia tietoja.  
Pyydämme Teitä valitsemaan sopivimmat vaihtoehdot:  
Henkilötunnus:  ___________________________                   
 




eronnut tai asumuserossa _____ 
leski _____ 
 
2) Mikä on koulutuksenne (korkein loppuun suoritettu koulutus) ? 
peruskoulu tai vähemmän _____ 
ammattikoulu _____ 
lukio _____ 




3) Mitä seuraavista oireista Teillä on esiintynyt ? 
vatsakivut _____ 








4) Kuinka usein nämä oireet häiritsevät Teitä? 
viikottain _____           kuukausittain _____       muutaman kuukauden välein _____ 
 
5) Jos olette työssä, kuinka paljon oireet vaikuttavat työntekoonne? 
en ole työssä _____ 
merkittävästi _____              jonkin verran _____           eivät lainkaan _____ 
 
6) Kuinka paljon oireet häiritsevät vapaa-ajan toimintaanne tai aktiviteettejanne?               
merkittävästi _____              jonkin verran _____             eivät lainkaan _____ 
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